Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

LYRA

Lyra Therapeutics Inc

Feb 13 • 04:00PM ET

1.39

0.00 0.00 %

Healthcare • Biotechnology • USA • NASD

Peers: JNJ PFE MRK GSK BMY LLY REGN AMGN VRTX ALNY

| Held by: VXF

Index	-	P/E	-	EPS (ttm)	-23.78	Insider Own	7.93%	Shs Outstand	1.64M	Perf Week	-23.63%
Market Cap	2.47M	Forward P/E	-	EPS next Y	-	Insider Trans	-45.83%	Shs Float	1.63M	Perf Month	-26.46%
Enterprise Value	11.80M	PEG	-	EPS next Q	-	Inst Own	14.16%	Short Float	3.63%	Perf Quarter	-64.18%
Income	-32.95M	P/S	4.12	EPS this Y	-	Inst Trans	-65.74%	Short Ratio	0.67	Perf Half Y	-80.42%
Sales	0.60M	P/B	-	EPS next Y	-	ROA	-53.81%	Short Interest	0.06M	Perf YTD	-54.87%
Book/sh	-2.63	P/C	0.11	EPS next 5Y	-	ROE	-404.48%	52W High	37.50 -96.29%	Perf Year	-86.76%
Cash/sh	12.41	P/FCF	-	EPS past 3/5Y	24.62% -2.22%	ROIC	-147.30%	52W Low	1.21 14.60%	Perf 3Y	-98.90%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	75.25% -	Gross Margin	3.50%	Volatility	13.37% 14.57%	Perf 5Y	-99.80%
Dividend TTM	-	EV/Sales	19.67	EPS Y/Y TTM	68.97%	Oper. Margin	-5401.33%	ATR (14)	0.27	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.43	Sales Y/Y TTM	-59.21%	Profit Margin	-5491.17%	RSI (14)	32.02	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.43	EPS Q/Q	62.68%	SMA20	-24.21%	Beta	-0.02	Target Price	7.00
Payout	-	Debt/Eq	-	Sales Q/Q	-87.18%	SMA50	-50.77%	Rel Volume	0.00	Prev Close	1.39
Employees	30	LT Debt/Eq	-	Earnings	Nov 12 AMC	SMA200	-78.04%	Avg Volume	87.86K	Price	1.39
IPO	May 01, 2020	Option/Short	No / Yes	EPS/Sales Surpr.	35.68% -87.85%	Trades		Volume	0	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
May-07-24	Downgrade	Jefferies	Buy → Hold	$10 → $0.50
May-07-24	Downgrade	H.C. Wainwright	Buy → Neutral	$12 → $2
May-07-24	Downgrade	BofA Securities	Buy → Underperform
May-06-24	Downgrade	William Blair	Outperform → Mkt Perform
Oct-06-23	Resumed	BTIG Research	Buy	$15
Aug-31-23	Initiated	H.C. Wainwright	Buy	$12
May-24-22	Initiated	Cantor Fitzgerald	Overweight	$15
May-26-20	Initiated	William Blair	Outperform
May-26-20	Initiated	Jefferies	Buy	$24
May-26-20	Initiated	BTIG Research	Buy	$28
May-26-20	Initiated	BofA/Merrill	Buy	$21

Show Previous Ratings

Jan-13-26 07:26AM	Lyra Therapeutics suspends further development of LYR-210 (TipRanks)
Jan-12-26 07:00AM	Lyra Therapeutics Provides Corporate Update (GlobeNewswire) -45.31%
Nov-12-25 05:15PM	Lyra Therapeutics, Inc. (LYRA) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -8.49%
04:01PM	Lyra Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-10-25 05:45PM	Assertio (ASRT) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
09:15AM	Loading…
Nov-06-25 09:15AM	Dentsply International (XRAY) Lags Q3 Earnings Estimates (Zacks) -12.81%
Nov-04-25 09:15AM	Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -5.30%
Oct-06-25 07:00AM	Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study (GlobeNewswire) +15.57%
Aug-12-25 05:15PM	Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Beats Revenue Estimates (Zacks) +8.00%
04:01PM	Lyra Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-08-25 08:55AM	Heron Therapeutics (HRTX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
Jun-27-25 08:00AM	Lyra Therapeutics Announces Up to Approximately $15 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -31.91%
Jun-12-25 12:00PM	Lyra Therapeutics (LYRA) Upgraded to Buy: Here's Why (Zacks) -12.22%
Jun-05-25 12:55PM	Lyra Stock Soars 356% in a Week on Strong Rhinosinusitis Study Success (Zacks) +11.00%
Jun-02-25 12:08PM	Lyra Therapeutics Shares Climb Over 500% After Major CRS Trial Win (GuruFocus.com) +310.75%
07:00AM	Loading…
07:00AM	Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS) (GlobeNewswire)
May-07-25 07:00AM	Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025 (GlobeNewswire)
May-06-25 05:20PM	Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:01PM	Lyra Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-31-25 06:55PM	Vivos Therapeutics, Inc. (VVOS) Reports Q4 Loss, Lags Revenue Estimates (Zacks) -9.07%
Mar-13-25 04:01PM	Lyra Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jan-09-25 12:00PM	Lyra Therapeutics (LYRA) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
Nov-12-24 05:15PM	Lyra Therapeutics, Inc. (LYRA) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -28.11%
04:01PM	Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-15-24 07:00AM	Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis (GlobeNewswire)
Sep-27-24 07:00AM	Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings (GlobeNewswire) +10.07%
Aug-14-24 09:54PM	LYRA Stock Earnings: Lyra Therapeutics Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace)
05:30PM	Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Lyra Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-15-24 11:35AM	Lyra Therapeutics, Inc. (LYRA): A Good Penny Stock to Buy For Under $1? (Insider Monkey)
10:31AM	Loading…
May-21-24 10:31AM	Lyra Therapeutics Reduces Workforce to Extend Cash Runway (MT Newswires)
09:14AM	Lyra Therapeutics Announces Cost-Cutting Measures to Preserve Capital (GlobeNewswire)
May-07-24 09:54AM	Target upgraded, CVS downgraded: Wall Street's top analyst calls (The Fly) -19.46%
07:39AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
07:38AM	--HC Wainwright Downgrades Lyra Therapeutics to Neutral From Buy (MT Newswires)
May-06-24 12:08PM	DJT Stock: Trump Media Fires Accounting Firm, Hires Replacement After SEC Charges (InvestorPlace) -87.06%
11:32AM	ZK Stock IPO: When Does Zeekr Go Public? What Is the Zeekr IPO Price Range? (InvestorPlace)
11:07AM	Warren Buffett Just Gave Up on Paramount (PARA) Stock (InvestorPlace)
10:51AM	Why Is Lyra Therapeutics (LYRA) Stock Down 90% Today? (InvestorPlace)
08:52AM	Lyra Therapeutics Phase 3 Trial of LYR-210 Falls Short of Primary Endpoint, Plans to Cut Staff; Shares Drop Pre-Bell (MT Newswires)
07:59AM	Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis (GlobeNewswire)
Apr-30-24 09:56PM	LYRA Stock Earnings: Lyra Therapeutics Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace) +9.09%
05:30PM	Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:04PM	Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-26-24 04:51PM	Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -8.70%
Mar-28-24 07:08AM	Lyra Therapeutics (LYRA) Soars 6.5%: Is Further Upside Left in the Stock? (Zacks)
Mar-25-24 08:50AM	Lyra Therapeutics (LYRA) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Mar-23-24 05:31AM	Lyra Therapeutics Inc (LYRA) Posts Year-End Financial Results, Aligns with EPS Projections (GuruFocus.com)
Mar-22-24 09:55AM	Wall Street Analysts See a 101.81% Upside in Lyra Therapeutics (LYRA): Can the Stock Really Move This High? (Zacks)
Mar-21-24 10:54PM	LYRA Stock Earnings: Lyra Therapeutics Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace)
04:01PM	Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-08-24 08:50AM	Here's Why Momentum in Lyra Therapeutics, Inc. (LYRA) Should Keep going (Zacks)
Mar-01-24 04:01PM	Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +8.17%
Feb-26-24 03:58AM	Strength Seen in Lyra Therapeutics, Inc. (LYRA): Can Its 6.9% Jump Turn into More Strength? (Zacks)
Feb-21-24 08:50AM	Here's What Could Help Lyra Therapeutics, Inc. (LYRA) Maintain Its Recent Price Strength (Zacks)
Jan-17-24 08:50AM	What Makes Lyra Therapeutics, Inc. (LYRA) a Good Fit for 'Trend Investing' (Zacks)
Nov-07-23 04:01PM	Lyra Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
07:00AM	Lyra Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-16-23 07:00AM	Lyra Therapeutics Announces Appointment of Ronan O'Brien as Chief Legal Officer (GlobeNewswire)
Sep-13-23 01:22PM	Lyra (LYRA) Posts Upbeat Data on Rhinosinusitis Study, Stock Up (Zacks)
Sep-12-23 07:00AM	Lyra Therapeutics Announces Positive Topline Results from BEACON Phase 2 Study of LYR-220 for the Treatment of Chronic Rhinosinusitis (CRS) in Patients with Prior Ethmoid Sinus Surgery (GlobeNewswire) +7.48%
Sep-06-23 08:00AM	Lyra Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-29-23 07:00AM	Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN I Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis (GlobeNewswire)
Aug-08-23 05:50PM	Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Lyra Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-13-23 07:30AM	Lyra Therapeutics to Present at William Blair Virtual Biotechnology Conference (GlobeNewswire)
Jun-02-23 04:01PM	Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.14%
07:30AM	Lyra Therapeutics to Present at Jefferies Healthcare Conference (GlobeNewswire)
Jun-01-23 07:29AM	Lyra Therapeutics Announces Closing of $50.0 Million Private Placement (GlobeNewswire) +5.06%
May-26-23 07:57AM	Lyra Therapeutics Announces $50.0 Million Private Placement (GlobeNewswire) +6.58%
May-14-23 08:19AM	Lyra Therapeutics First Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags (Simply Wall St.)
May-12-23 08:15AM	Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Lyra Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
May-09-23 04:01PM	Lyra Therapeutics to Present at Bank of America Securities 2023 Healthcare Conference (GlobeNewswire)
Apr-29-23 08:19AM	Lyra Therapeutics, Inc.'s (NASDAQ:LYRA) biggest owners are retail investors who got richer after stock soared 18% last week (Simply Wall St.)
Apr-25-23 07:59AM	Lyra Therapeutics Announces Restart of Pivotal Phase 3 ENLIGHTEN II Clinical Trial of LYR-210 in Chronic Rhinosinusitis (GlobeNewswire)
Mar-29-23 04:06PM	Lyra Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-20-23 01:11PM	Estimating The Intrinsic Value Of Lyra Therapeutics, Inc. (NASDAQ:LYRA) (Simply Wall St.)
Mar-01-23 05:21AM	Assertio (ASRT) Soars 5.1%: Is Further Upside Left in the Stock? (Zacks) -5.04%
Feb-28-23 05:17AM	Lyra Therapeutics, Inc. (NASDAQ:LYRA) insiders placed bullish bets worth US$1.5m in the last 12 months (Simply Wall St.)
Feb-27-23 07:59AM	Lyra Therapeutics Announces Appointment of John Bishop, Ph.D., as Chief Technology Officer (GlobeNewswire)
Feb-07-23 01:23PM	Here's Why We're Watching Lyra Therapeutics' (NASDAQ:LYRA) Cash Burn Situation (Simply Wall St.)
Feb-06-23 07:56AM	Lyra Therapeutics Announces Completion of Enrollment in the BEACON Phase 2 Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients (GlobeNewswire)
Jan-17-23 06:42PM	Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-20-22 08:52AM	Further weakness as Lyra Therapeutics (NASDAQ:LYRA) drops 15% this week, taking one-year losses to 49% (Simply Wall St.)
Nov-09-22 08:00AM	Lyra Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) -15.52%
Nov-08-22 05:45PM	Lyra Therapeutics, Inc. (LYRA) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:01PM	Lyra Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Sep-21-22 06:11AM	Bullish insiders at Lyra Therapeutics, Inc. (NASDAQ:LYRA) loaded up on US$1.5m of stock earlier this year (Simply Wall St.)
Sep-13-22 04:01PM	Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
07:00AM	Lyra Therapeutics Advances Phase 2 BEACON Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients to Randomized Stage of Study (PR Newswire)
Sep-10-22 08:00AM	LYRA THERAPEUTICS announces additional data presentations FROM PHASE 2 LANTERN STUDY at the americal rhinologic society annual meeting (PR Newswire)
Sep-08-22 07:00AM	Lyra Therapeutics Announces First Patient Enrolled in Pivotal ENLIGHTEN II Clinical Trial of LYR-210 in Chronic Rhinosinusitis Patients (PR Newswire)
Sep-06-22 07:00AM	Lyra Therapeutics to Present at the H.C. Wainwright AnnualGlobal Investment Conference 2022 (PR Newswire)
Aug-31-22 02:08PM	We're Hopeful That Lyra Therapeutics (NASDAQ:LYRA) Will Use Its Cash Wisely (Simply Wall St.)
Aug-29-22 07:00AM	Lyra Therapeutics to Present Additional LANTERN Phase 2 Study Results for LYR210 in Two Oral Presentations at ARS Annual Meeting (PR Newswire) +8.52%
Aug-11-22 08:05AM	Are Institutions Heavily Invested In Lyra Therapeutics, Inc.'s (NASDAQ:LYRA) Shares? (Simply Wall St.)
Aug-09-22 08:25AM	Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Lyra Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update (PR Newswire)
Jul-27-22 09:40AM	Has Lyra Therapeutics (LYRA) Outpaced Other Medical Stocks This Year? (Zacks)

Lyra Therapeutics, Inc. is a clinical-stage therapeutics company. It develops novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat, or ENT, diseases. The firms proprietary XTreo deliver medicines. The company was founded by Carmichael S. Roberts, George M. Whitesides, and Robert S. Langer in November 2005 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Palasis Maria	Officer	Jan 27 '26	Proposed Sale	1.71	1,895	3,248		Jan 27 03:39 PM
Cavalier Jason	Chief Financial Officer	Jan 06 '26	Sale	3.36	769	2,587	518,547	Jan 08 04:30 PM
Palasis Maria	President & CEO	Jan 06 '26	Sale	3.36	1,702	5,726	1,096,733	Jan 08 04:30 PM
Palasis Maria	Officer	Jan 06 '26	Proposed Sale	3.36	1,702	5,725		Jan 06 04:32 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Nov 13 '25	Sale	3.90	31,810	124,062	14,026	Nov 13 05:07 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Nov 12 '25	Sale	4.06	8,745	35,499	17,239	Nov 13 05:07 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Nov 11 '25	Sale	4.31	5,320	22,954	18,122	Nov 13 05:07 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Nov 06 '25	Sale	5.18	32,149	166,529	22,521	Nov 10 05:08 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Nov 07 '25	Sale	4.75	19,739	93,695	20,528	Nov 10 05:08 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Nov 10 '25	Sale	4.54	18,502	83,995	18,659	Nov 10 05:08 PM
Palasis Maria	Officer	Oct 14 '25	Proposed Sale	7.23	537	3,881		Oct 14 03:09 PM
Palasis Maria	President & CEO	Jul 10 '25	Sale	8.91	1,565	13,944	1,098,435	Jul 14 09:27 PM
Cavalier Jason	Chief Financial Officer	Jul 10 '25	Sale	8.91	684	6,094	519,316	Jul 14 09:27 PM
Palasis Maria	Officer	Jul 10 '25	Proposed Sale	8.91	1,565	13,945		Jul 10 04:05 PM
Waksal Harlan	Officer	Apr 25 '25	Proposed Sale	0.10	145,370	14,930		Apr 25 03:41 PM
Palasis Maria	Officer	Apr 09 '25	Proposed Sale	0.09	39,567	3,545		Apr 09 03:44 PM

Open in Screener

OBIO

Orchestra BioMed Holdings Inc

Feb 13 • 04:00PM ET

3.83

0.00 0.00 %

Healthcare • Biotechnology • USA • NASD

OBIO Orchestra BioMed Holdings Inc daily Stock Chart

Peers: BSX ABT MDT JNJ STXS SYK IART STE GMED PEN

| Held by: VTI VXF SCHA IWC SCHB AVSC IBBQ BIB

Index	-	P/E	-	EPS (ttm)	-1.82	Insider Own	23.20%	Shs Outstand	56.46M	Perf Week	-2.05%
Market Cap	216.26M	Forward P/E	-	EPS next Y	-1.60	Insider Trans	0.17%	Shs Float	43.35M	Perf Month	-14.13%
Enterprise Value	152.64M	PEG	-	EPS next Q	-0.38	Inst Own	39.50%	Short Float	1.91%	Perf Quarter	-13.35%
Income	-75.10M	P/S	76.69	EPS this Y	-4.91%	Inst Trans	9.86%	Short Ratio	3.54	Perf Half Y	43.98%
Sales	2.82M	P/B	4.94	EPS next Y	8.22%	ROA	-83.39%	Short Interest	0.83M	Perf YTD	-7.71%
Book/sh	0.77	P/C	2.26	EPS next 5Y	8.52%	ROE	-166.97%	52W High	5.98 -35.95%	Perf Year	-31.61%
Cash/sh	1.70	P/FCF	-	EPS past 3/5Y	-347.45% -273.68%	ROIC	-99.81%	52W Low	2.20 74.09%	Perf 3Y	-54.40%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	82.82%	Volatility	7.88% 8.29%	Perf 5Y	-73.35%
Dividend TTM	-	EV/Sales	54.13	EPS Y/Y TTM	-14.32%	Oper. Margin	-2669.91%	ATR (14)	0.32	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.72	Sales Y/Y TTM	6.46%	Profit Margin	-2665.05%	RSI (14)	44.84	Recom	1.38
Dividend Gr. 3/5Y	- -	Current Ratio	4.73	EPS Q/Q	2.66%	SMA20	-3.16%	Beta	0.58	Target Price	13.43
Payout	-	Debt/Eq	0.74	Sales Q/Q	-12.77%	SMA50	-9.68%	Rel Volume	0.00	Prev Close	3.83
Employees	70	LT Debt/Eq	0.72	Earnings	Nov 10 AMC	SMA200	12.20%	Avg Volume	233.13K	Price	3.83
IPO	Aug 04, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-0.65% 16.13%	Trades		Volume	0	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-10-25	Initiated	TD Cowen	Buy	$15
Aug-20-25	Downgrade	BTIG Research	Buy → Neutral
Mar-20-25	Initiated	BTIG Research	Buy	$12
Jan-02-25	Initiated	Barclays	Overweight	$16
Aug-22-24	Initiated	H.C. Wainwright	Buy	$14
Jul-25-24	Initiated	B. Riley Securities	Buy	$15
Jan-19-24	Initiated	Jefferies	Buy	$14
Feb-24-23	Initiated	Piper Sandler	Overweight	$15
Feb-07-23	Initiated	Chardan Capital Markets	Buy	$20

Feb-13-26 04:05PM	Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-12-26 09:00AM	Orchestra BioMed to Receive Up to $21 Million in Proceeds from Acquisition of Vivasure by Haemonetics (GlobeNewswire)
Dec-31-25 11:13AM	TD Cowen Initiates Orchestra BioMed (OBIO), Cites High-Margin Potential in Lead Cardiovascular Programs (Insider Monkey)
Dec-08-25 07:00AM	Orchestra BioMed Announces AVIM Therapy and Virtue SAB Program Presentations at ICI Meeting (GlobeNewswire)
Nov-29-25 01:25AM	Analyst Confidence in Orchestra BioMed Holdings (OBIO) High Amid Key Clinical and Strategic Advancements (Insider Monkey)
04:05PM	Loading…
Nov-26-25 04:05PM	Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-11-25 09:00AM	Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences (GlobeNewswire) +8.47%
07:31AM	What To Expect From Orchestra BioMed Holdings Inc (OBIO) Q3 2025 Earnings (GuruFocus.com)
Nov-10-25 05:30PM	Orchestra BioMed Holdings, Inc. (OBIO) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
04:10PM	Orchestra BioMed Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates (GlobeNewswire)
08:40AM	ADC Therapeutics SA (ADCT) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
Nov-04-25 10:00AM	Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks) -5.32%
Nov-03-25 08:00AM	Orchestra BioMed to Host Business Update Call on November 12, 2025 (GlobeNewswire)
Oct-28-25 08:00AM	Orchestra BioMed and Terumo Enter into New $30 Million Virtue SAB Strategic Agreements (GlobeNewswire)
Oct-27-25 09:00AM	Orchestra BioMed Announces First Patients Enrolled in Virtue SAB US Pivotal IDE Coronary Trial (GlobeNewswire)
08:00AM	Loading…
Oct-09-25 08:00AM	Orchestra BioMed to Showcase Transformative Potential of AVIM Therapy in Keynote Presentation on Hypertensive Heart Disease at Georgia Innovation Summit (GlobeNewswire)
Sep-04-25 05:00PM	Orchestra BioMed Presents New AVIM Therapy Clinical Data at HRX Demonstrating Substantial and Sustained Blood Pressure Reductions that are Reproducible Upon Reactivation Following Washout (GlobeNewswire)
Aug-26-25 07:30AM	Orchestra BioMed Announces Publication of Clinical Data Demonstrating Favorable Blood Pressure and Hemodynamic Effects of AVIM Therapy in JACC: Clinical Electrophysiology (GlobeNewswire) +15.38%
Aug-14-25 08:00AM	Orchestra BioMed Announces Publication of AVIM Therapy Clinical Data in JACC: Advances Demonstrating Potential to Improve Cardiac Function in Patients with Hypertension and Diastolic Dysfunction (GlobeNewswire)
Aug-13-25 08:00AM	Campbellford Memorial Hospitals New Homecare Program Frees up 14.5 Hospital Bed-Days Per Patient Through a Partnership With Gotcare and OBIO® (Business Wire)
Aug-12-25 03:00PM	Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Beats Revenue Estimates (Zacks) +7.94%
08:14AM	Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates (GlobeNewswire)
Aug-08-25 07:00AM	Orchestra BioMed Announces Rollout of FDA-Approved BACKBEAT Global Pivotal Study Protocol Update Significantly Expanding Patient Eligibility (GlobeNewswire)
Aug-05-25 07:00AM	Orchestra BioMed Secures Over $111 Million in Proceeds and Committed Capital Following Completion of Strategic Transactions and Concurrent Public and Private Equity Offerings (GlobeNewswire)
Aug-04-25 05:55PM	CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Lags Revenue Estimates (Zacks) +9.84%
Aug-01-25 07:59AM	Orchestra BioMed Announces Pricing of $40 Million Public Offering (GlobeNewswire) -20.26%
Jul-31-25 04:02PM	Orchestra BioMed Announces Proposed Public Offering (GlobeNewswire)
04:01PM	Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed (GlobeNewswire)
Jul-16-25 08:00AM	OBIO® Paves the Way for Companies to Succeed in Canada as a Stepping Stone to New Global Markets (Business Wire) +7.88%
Jun-18-25 09:30AM	Orchestra BioMed Showcases AVIM Therapy as Purpose-Built Solution for Hypertensive Heart Disease at CSI Frankfurt 2025 (GlobeNewswire) -11.01%
08:00AM	Loading…
May-20-25 08:00AM	Sidoti Events, LLC's Virtual May Micro-Cap Conference (ACCESSWIRE)
May-12-25 05:40PM	Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +10.94%
04:28PM	Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones (GlobeNewswire)
May-07-25 08:30AM	Orchestra BioMed's AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart Failure (GlobeNewswire)
May-06-25 05:10PM	Ultragenyx (RARE) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -5.47%
May-05-25 10:00AM	Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks) -6.57%
Apr-29-25 09:00AM	Orchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head with Paclitaxel-Coated Balloon (GlobeNewswire)
Apr-28-25 04:30PM	Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences (GlobeNewswire) -6.12%
Apr-23-25 09:00AM	Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting (GlobeNewswire)
Apr-22-25 07:00AM	Orchestra BioMed Receives FDA Breakthrough Device Designation for AVIM Therapy (GlobeNewswire)
Mar-31-25 07:05PM	Orchestra BioMed Holdings, Inc. (OBIO) Reports Q4 Loss, Lags Revenue Estimates (Zacks) -24.30%
04:21PM	Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update (GlobeNewswire)
Mar-24-25 09:10AM	Clene Inc. (CLNN) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
Feb-20-25 08:00AM	Orchestra BioMed to Present at Upcoming Investor Conferences (GlobeNewswire) -8.77%
Feb-18-25 08:00AM	Orchestra BioMed Appoints Vivek Reddy, M.D. as Executive Chairman of the BACKBEAT Study Steering Committee and Chairman of Bioelectronic Therapies Scientific Advisory Board (GlobeNewswire)
Feb-12-25 10:43AM	Orchestra BioMed Announces Data Demonstrating Favorable Impact of AVIM Therapy on Diastolic Dysfunction, a Key Driver of Heart Failure Progression, will be Presented as Late-Breaking Science at the THT 2025 Conference (GlobeNewswire)
Feb-05-25 08:00AM	Orchestra BioMed Announces Appointment of Former Medtronic SVP of Corporate Development Christopher Cleary to Board of Directors (GlobeNewswire)
Dec-09-24 07:00AM	Orchestra BioMed Announces AVIM Therapy Program Presentations at ICI Meeting (GlobeNewswire) +9.54%
Nov-26-24 04:05PM	Orchestra BioMed to Participate in the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
Nov-12-24 06:05PM	Orchestra BioMed Holdings, Inc. (OBIO) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -7.67% +7.24%
04:12PM	Orchestra BioMed Reports Third Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire)
Nov-07-24 08:00AM	Orchestra BioMed to Participate in Jefferies London Healthcare Conference (GlobeNewswire) -5.50%
Aug-12-24 05:35PM	Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:20PM	Orchestra BioMed Reports Second Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire)
Aug-08-24 09:35AM	Orchestra BioMed Holdings, Inc. (OBIO) Loses -25.35% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) +13.55%
Aug-01-24 10:01AM	Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Should You Buy? (Zacks) -7.18%
Jul-30-24 08:00AM	Orchestra BioMed Announces Appointment of Cardiovascular Device Industry Expert John Mack to Board of Directors (GlobeNewswire)
Jul-26-24 12:00PM	Orchestra BioMed Holdings, Inc. (OBIO) Upgraded to Buy: Here's What You Should Know (Zacks) -6.70%
09:55AM	Wall Street Analysts Believe Orchestra BioMed Holdings, Inc. (OBIO) Could Rally 102.61%: Here's is How to Trade (Zacks)
Jul-23-24 09:00AM	Precision Neuroscience Expands Executive Team as Brain Computer Interface Industry Rapidly Advances (GlobeNewswire)
Jun-24-24 08:07AM	Orchestra BioMed Holdings, Inc. (OBIO) Stock Jumps 7.3%: Will It Continue to Soar? (Zacks) +9.02%
Jun-04-24 08:00AM	Orchestra BioMed Announces Further Details on In-Person R&D Day in New York Featuring Key Opinion Leaders to Discuss AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024 (GlobeNewswire) +10.64%
Jun-03-24 12:00PM	All You Need to Know About Orchestra BioMed Holdings, Inc. (OBIO) Rating Upgrade to Buy (Zacks)
09:55AM	Does Orchestra BioMed Holdings, Inc. (OBIO) Have the Potential to Rally 135.64% as Wall Street Analysts Expect? (Zacks)
May-22-24 08:43AM	Orchestra BioMed to Participate in Jefferies Global Healthcare Conference (GlobeNewswire)
May-13-24 09:53PM	OBIO Stock Earnings: Orchestra BioMed Hldgs Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace) +13.04%
06:05PM	Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:58PM	Orchestra BioMed Reports First Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire)
Apr-30-24 08:30AM	Orchestra BioMed Announces AVIM Therapy Global Intellectual Property Estate Reaches 110 Issued Patents (GlobeNewswire)
08:00AM	Orchestra BioMed to Host In-Person R&D Day in New York on AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024 (GlobeNewswire)
Mar-27-24 04:17PM	Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update (GlobeNewswire)
Mar-26-24 08:00AM	Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors (GlobeNewswire) +5.20%
Mar-13-24 08:00AM	Orchestra BioMed Demonstrates Strength of Cardiovascular Pipeline with Virtue SAB and AVIM Therapy Presentations at CRT 2024 Annual Meeting (GlobeNewswire)
Mar-07-24 08:00AM	Orchestra BioMed to Participate in Upcoming Investor Conferences (GlobeNewswire) -6.62%
Mar-06-24 08:37AM	Orchestra BioMed Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker Patients (GlobeNewswire)
Feb-26-24 08:00AM	Orchestra BioMed Presents New Data Showing Sustained Clinically Meaningful Reduction in 24-Hour Ambulatory Systolic Blood Pressure in Hypertensive Pacemaker Patients Treated with AVIM Therapy for Over 3 Years (GlobeNewswire)
Feb-16-24 09:13AM	Why Orchestra BioMed (OBIO) Might Surprise This Earnings Season (Zacks) -8.45%
Jan-08-24 07:30AM	Orchestra BioMed Announces Initiation of BACKBEAT Pivotal Study of AVIM Therapy in Hypertensive Pacemaker Patients (GlobeNewswire) +9.38%
Nov-13-23 04:21PM	Orchestra BioMed Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) +14.61% +13.08%
Nov-09-23 04:42PM	Orchestra BioMed to Present at Upcoming Investor Conferences (GlobeNewswire)
Oct-30-23 03:52PM	Billionaire Marc Lasrys Top 10 Stock Picks (Insider Monkey)
Sep-22-23 11:27AM	Lab Notes: Main Line firm spins off company that will focus on OTC product pipeline (American City Business Journals)
Sep-19-23 02:37PM	Rebel's Edge - September 19: $NIO, $BHC, $OBIO, and the Firing of MSU's Football Coach (TheStreet.com) +27.61%
07:30AM	Orchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT for the Treatment of Hypertension in Pacemaker Patients (GlobeNewswire)
Sep-06-23 05:00PM	Motus GI Appoints Medical Device Industry Veteran Scott Durbin to its Board of Directors (GlobeNewswire) -7.74%
Aug-10-23 04:34PM	Orchestra BioMed Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) +7.05%
Aug-08-23 08:30AM	Orchestra BioMed Granted FDA Approval of IDE for U.S. Pivotal Study of Virtue® Sirolimus AngioInfusion Balloon in Patients with Coronary In-Stent Restenosis (GlobeNewswire)
Jul-27-23 09:47AM	Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) stock most popular amongst retail investors who own 36%, while hedge funds hold 28% (Simply Wall St.) -14.00%
Jun-28-23 02:16PM	Why Shares of Orchestra BioMed Holdings Jumped Wednesday (Motley Fool) +24.85%
Jun-26-23 08:00AM	Orchestra BioMed Set to Join Russell 3000® and other FTSE Russell Indexes (GlobeNewswire) -9.81%
Jun-07-23 08:30AM	Orchestra BioMed Appoints Bill Little as Executive Vice President of Corporate Development and Strategy and Andrew Taylor as Chief Financial Officer (GlobeNewswire) -6.42%
Jun-01-23 08:00AM	Orchestra BioMed to Present at the Jefferies Global Healthcare Conference (GlobeNewswire) +8.93%
May-12-23 09:15AM	Orchestra BioMed Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Apr-11-23 05:39AM	3 Stocks That Already Doubled in 2023 and Could Keep Climbing (Motley Fool) +10.12%
Mar-27-23 06:05AM	Orchestra BioMed Holdings Full Year 2022 Earnings: US$14.60 loss per share (vs US$10.90 loss in FY 2021) (Simply Wall St.)
Mar-24-23 03:52PM	Why Shares of Orchestra BioMed Jumped This Week (Motley Fool)
Mar-07-23 08:00AM	Orchestra BioMed to Present at Upcoming Investor Conferences (GlobeNewswire) -6.77%
Feb-24-23 08:00AM	Orchestra BioMed Announces Upcoming Presentations on BackBeat CNT and Virtue® SAB at CRT 2023 (GlobeNewswire)
Feb-07-23 08:00AM	Orchestra BioMed Strengthens Senior Leadership Team (GlobeNewswire)

Orchestra Biomed Holdings, Inc. engages in the provision of biomedical technologies to patients through risk-reward-sharing partnerships with medical device companies. The company was founded by David P. Hochman on May 25, 2020 and is headquartered in New Hope, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hochman David P	See Remarks	Nov 14 '25	Buy	4.07	5,000	20,350	612,822	Nov 17 05:00 PM
Aryeh Jason	Director	Sep 19 '25	Buy	2.45	1,000	2,450	108,482	Sep 19 06:57 PM
Fain Eric S	Director	Aug 25 '25	Buy	2.61	5,760	15,034	71,709	Aug 25 07:04 PM
Sherman Darren	See Remarks	Aug 25 '25	Buy	2.62	3,000	7,860	926,837	Aug 25 07:04 PM
Hochman David P	See Remarks	Aug 21 '25	Buy	2.49	6,000	14,940	651,460	Aug 25 07:03 PM
Taylor Andrew Lawrence	Chief Financial Officer	Aug 25 '25	Buy	2.55	2,000	5,100	482,788	Aug 25 07:01 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Aug 01 '25	Buy	2.75	700,000	1,925,000	5,292,556	Aug 05 10:46 AM
Hochman David P	See Remarks	Aug 04 '25	Buy	2.75	20,000	55,000	349,331	Aug 04 06:16 PM
Fain Eric S	Director	Jun 26 '25	Sale	3.05	2,683	8,183	50,949	Jun 27 05:10 PM
Fain Eric S	Director	Jun 26 '25	Proposed Sale	3.05	2,683	8,194		Jun 26 03:11 PM
RTW INVESTMENTS, LP	10% Owner	Apr 30 '25	Buy	2.99	49,900	149,201	8,306,063	May 01 08:18 AM
RTW INVESTMENTS, LP	10% Owner	Apr 29 '25	Buy	2.53	50,000	126,500	8,256,163	Apr 29 05:16 PM

Open in Screener

ACRV

Acrivon Therapeutics Inc

Feb 13 • 04:00PM ET

1.63

0.00 0.00 %

Healthcare • Biotechnology • USA • NASD

ACRV Acrivon Therapeutics Inc daily Stock Chart

Peers: BMRN VRTX REGN AMGN GILD BIIB EXEL INCY NBIX IONS

| Held by: VTI VXF IWC CHNA

Index	-	P/E	-	EPS (ttm)	-2.13	Insider Own	29.64%	Shs Outstand	31.55M	Perf Week	-2.40%
Market Cap	51.43M	Forward P/E	-	EPS next Y	-1.96	Insider Trans	0.73%	Shs Float	22.20M	Perf Month	-10.93%
Enterprise Value	-74.83M	PEG	-	EPS next Q	-0.48	Inst Own	50.48%	Short Float	9.12%	Perf Quarter	-28.51%
Income	-81.75M	P/S	-	EPS this Y	14.91%	Inst Trans	1.04%	Short Ratio	1.30	Perf Half Y	17.27%
Sales	0.00M	P/B	0.40	EPS next Y	3.37%	ROA	-45.42%	Short Interest	2.02M	Perf YTD	-32.37%
Book/sh	4.08	P/C	0.40	EPS next 5Y	6.86%	ROE	-50.23%	52W High	6.08 -73.19%	Perf Year	-69.59%
Cash/sh	4.10	P/FCF	-	EPS past 3/5Y	-45.20% -74.96%	ROIC	-62.69%	52W Low	1.05 55.24%	Perf 3Y	-92.88%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	8.35% 7.77%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	21.17%	Oper. Margin	-	ATR (14)	0.17	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	8.75	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	40.61	Recom	1.22
Dividend Gr. 3/5Y	- -	Current Ratio	8.75	EPS Q/Q	19.70%	SMA20	-9.47%	Beta	1.77	Target Price	11.50
Payout	-	Debt/Eq	0.02	Sales Q/Q	-	SMA50	-22.87%	Rel Volume	0.00	Prev Close	1.63
Employees	78	LT Debt/Eq	0.01	Earnings	Nov 13 AMC	SMA200	-3.45%	Avg Volume	1.56M	Price	1.63
IPO	Nov 15, 2022	Option/Short	No / Yes	EPS/Sales Surpr.	20.49% -	Trades		Volume	0	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
May-05-25	Resumed	Piper Sandler	Overweight	$6
Jan-31-25	Initiated	KeyBanc Capital Markets	Overweight
Sep-16-24	Upgrade	Ladenburg Thalmann	Neutral → Buy	$16
Apr-29-24	Downgrade	Ladenburg Thalmann	Buy → Neutral
Mar-01-24	Initiated	JMP Securities	Mkt Outperform	$14
Dec-15-23	Resumed	Jefferies	Buy	$17 → $12
Oct-05-23	Initiated	Maxim Group	Buy
Jun-02-23	Initiated	Oppenheimer	Outperform	$25
May-08-23	Initiated	BMO Capital Markets	Outperform	$25
Apr-27-23	Initiated	Ladenburg Thalmann	Buy	$22
Apr-20-23	Initiated	H.C. Wainwright	Buy	$24
Dec-12-22	Initiated	Piper Sandler	Overweight	$25
Dec-12-22	Initiated	Jefferies	Buy	$17
Dec-12-22	Initiated	Cowen	Outperform

Show Previous Ratings

Jan-28-26 09:15AM	Late-Stage Breakthroughs: How 2026's Top Clinical Platforms Are Redefining Cancer Treatment (PR Newswire)
Jan-23-26 08:11AM	Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (ESGO) Annual International Congress (GlobeNewswire)
Jan-08-26 02:02PM	Small-Cap Acrivon Highlights Tumor Shrinkage And Trial Progress Across Key Studies, Stock Falls (Benzinga) -34.58%
07:30AM	Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 (GlobeNewswire)
Jan-07-26 09:40AM	Is Humacyte, Inc. (HUMA) Outperforming Other Medical Stocks This Year? (Zacks)
07:30AM	Loading…
Jan-06-26 07:30AM	Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast (GlobeNewswire) +31.44%
Dec-17-25 09:34AM	UPDATE -- Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast (GlobeNewswire)
07:30AM	Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates (GlobeNewswire)
Nov-29-25 01:26AM	H.C. Wainwright Initiates Coverage on Acrivon Therapeutics (ACRV) With "Buy" Rating and $19 PT (Insider Monkey)
Nov-13-25 04:10PM	Acrivon Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights (GlobeNewswire) -9.21% +8.21%
Nov-02-25 05:05AM	Analysts Predict Up to 550% Rally for These 2 Strong Buy Penny Stocks (TipRanks)
Oct-22-25 04:15PM	Acrivon Therapeutics Highlights its Powerful Generative Phosphoproteomics AP3 Platform with Compelling Preclinical Data for ACR-2316 with Three Presentations at the Upcoming AACR-NCI-EORTC International Conference (GlobeNewswire)
Oct-01-25 04:30PM	Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-13-25 04:15PM	Acrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights (GlobeNewswire) +6.11%
May-17-25 12:30PM	Acrivon Therapeutics downgraded to Hold from Buy at JonesResearch (TipRanks)
04:10PM	Loading…
May-14-25 04:10PM	Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights (GlobeNewswire)
May-05-25 09:55AM	Here's Why Acrivon Therapeutics, Inc. (ACRV) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Apr-28-25 12:23PM	Can Humana Beat Q1 Earnings Estimates on Growing Premiums? (Zacks) -5.49%
Apr-25-25 08:00AM	Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025 (GlobeNewswire) -17.59%
Apr-24-25 11:00AM	Universal Health to Report Q1 Earnings: Can it Surprise Wall Street? (Zacks)
Apr-23-25 01:41PM	HCA Healthcare to Report Q1 Earnings: Key Estimates to Note (Zacks)
01:28PM	Can Centene Beat Q1 Earnings Estimates on Growing Premiums? (Zacks)
Apr-22-25 11:19AM	Molina Healthcare to Report Q1 Earnings: Key Estimates to Watch (Zacks) +6.28%
Apr-14-25 09:35AM	Down -70.22% in 4 Weeks, Here's Why You Should You Buy the Dip in Acrivon Therapeutics, Inc. (ACRV) (Zacks) -7.41%
Apr-07-25 04:05PM	Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer (GlobeNewswire) -7.95%
Mar-28-25 12:00PM	Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's What You Should Know (Zacks) -11.11%
09:35AM	Here's Why Acrivon Therapeutics, Inc. (ACRV) is Poised for a Turnaround After Losing -52.81% in 4 Weeks (Zacks)
Mar-27-25 05:44PM	Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Mar-19-25 08:00AM	Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program Updates (GlobeNewswire)
Feb-06-25 08:16AM	Acrivon Therapeutics announces FDA granted BDD for ACR-368 (TipRanks) -6.60%
04:54AM	Loading…
04:54AM	FDA grants breakthrough designation for Acrivons endometrial cancer assay (Medical Device Network)
Feb-05-25 03:45PM	Acrivon Therapeutics (ACRV): AI-Powered Precision Oncology Gets FDA Breakthrough Status (Insider Monkey) +17.94%
08:00AM	Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer (GlobeNewswire)
Nov-13-24 07:00AM	Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights (GlobeNewswire) -5.48%
Oct-17-24 08:00AM	Acrivon Therapeutics to Present Data Demonstrating Deployment of its AP3 Platform for Streamlined Drug Discovery and Clinical Development at Two Scientific Conferences - Human Proteome Organization World Congress and EORTC-NCI-AACR Symposium (GlobeNewswire)
Oct-16-24 04:00PM	Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-12-24 08:28AM	Acrivon Therapeutics Launches Phase 1 Cancer Trial, Advances Oncology Pipeline (TipRanks)
Oct-11-24 08:00AM	Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity (GlobeNewswire)
Sep-14-24 03:10AM	Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis (GlobeNewswire)
Sep-10-24 08:00AM	Acrivon Therapeutics to Present at the Cantor Global Healthcare Conference (GlobeNewswire) +8.61%
Sep-09-24 07:00AM	Acrivon Therapeutics to Host Virtual Investor Event to Review Positive Phase 2 Clinical Data of ACR-368 Presented at ESMO and Pipeline Progress, Including Clinical Candidate ACR-2316 (GlobeNewswire)
Aug-15-24 09:40AM	Are Medical Stocks Lagging Acrivon Therapeutics, Inc. (ACRV) This Year? (Zacks)
Aug-13-24 08:00AM	Acrivon Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
Jun-21-24 09:40AM	Is Acrivon Therapeutics, Inc. (ACRV) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jun-05-24 09:40AM	Is Acrivon Therapeutics, Inc. (ACRV) Outperforming Other Medical Stocks This Year? (Zacks)
May-29-24 08:00AM	Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-28-24 09:47AM	Here's Why You Should Buy Acrivon Therapeutics (ACRV) Stock (Zacks)
May-20-24 09:40AM	Has Acrivon Therapeutics, Inc. (ACRV) Outpaced Other Medical Stocks This Year? (Zacks)
May-14-24 01:54PM	ACRV Stock Earnings: Acrivon Therapeutics Beats EPS for Q1 2024 (InvestorPlace)
08:00AM	Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
May-10-24 08:50AM	Is a Surprise Coming for Acrivon Therapeutics (ACRV) This Earnings Season? (Zacks) +7.74%
Apr-29-24 07:08AM	Ladenburg Thalmann Downgrades Acrivon Therapeutics to Neutral (MT Newswires) +18.20%
Apr-24-24 04:01PM	Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event (GlobeNewswire) -10.84%
Apr-16-24 08:01PM	Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316 (GlobeNewswire) +9.19%
Apr-10-24 08:00AM	Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistance Mechanisms to ACR-368 (GlobeNewswire) +8.00%
Apr-09-24 10:32AM	ACRV Stock Jumps 55% as Acrivon Therapeutics Gets $130 Million Boost (InvestorPlace) +62.77%
07:00AM	Acrivon Therapeutics Announces $130 Million Private Placement Financing (GlobeNewswire)
Mar-30-24 05:31AM	Acrivon Therapeutics Inc (ACRV) Reports Increased Annual Loss: A Detailed Look Against Analyst ... (GuruFocus.com)
Mar-28-24 12:52PM	ACRV Stock Earnings: Acrivon Therapeutics Misses EPS for Q4 2023 (InvestorPlace) +10.60%
08:00AM	Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights (GlobeNewswire)
Mar-05-24 04:30PM	Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316 (GlobeNewswire)
Mar-04-24 08:00AM	Acrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare Investor, to its Board of Directors (GlobeNewswire) -11.40%
Feb-27-24 08:00AM	Acrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care Conference (GlobeNewswire) +22.07%
Feb-08-24 08:00AM	Acrivon Therapeutics Appoints Seasoned Industry Executive Ivana Magov evi -Liebisch, Ph.D., J.D., to Board of Directors (GlobeNewswire)
Feb-06-24 08:00AM	Acrivon Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-12-24 04:00PM	Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.31%
Jan-04-24 08:00AM	Acrivon Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -6.63%
Jan-03-24 08:00AM	Acrivon Therapeutics Appoints Jean-Marie Cuillerot, M.D., as Chief Medical Officer (GlobeNewswire)
Nov-28-23 08:00AM	Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Ovarian Cancer (GlobeNewswire)
Nov-21-23 08:00AM	Acrivon Therapeutics to Present at the Piper Sandler Annual Healthcare Conference (GlobeNewswire) -9.02%
08:00AM	Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-09-23 08:01AM	Acrivon Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights (GlobeNewswire) -19.19%
Oct-16-23 08:00AM	Acrivon Therapeutics Presents Data Demonstrating Capabilities of its AP3 Platform and ACR-368 OncoSignature Assay for Patient Responder Identification at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Sep-28-23 04:05PM	Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-19-23 04:32PM	Acrivon Therapeutics to Highlight its ACR-368 OncoSignature Test, Used in Ongoing Phase 2 Study to Treat Patients Based on Predicted Sensitivity to Monotherapy with its CHK1/2 Inhibitor ACR-368, at the Upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Sep-05-23 04:05PM	Acrivon Therapeutics Announces ACR-2316, a Novel Dual WEE1 and PKMYT1 Inhibitor Development Candidate, Designed Using Acrivons AP3 Platform to Achieve Potent Single Agent Activity, as Demonstrated in Preclinical Studies (GlobeNewswire)
Aug-30-23 08:00AM	Acrivon Therapeutics to Participate in Two Investor Conferences in September (GlobeNewswire)
Aug-17-23 04:00PM	Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-11-23 07:00AM	Acrivon Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights (GlobeNewswire) +6.81%
Aug-08-23 12:38PM	Q2 2023 Akoya Biosciences Inc Earnings Call (Thomson Reuters StreetEvents)
Jul-20-23 08:00AM	Acrivon Therapeutics Announces the Appointment of Adam Levy, Ph.D., M.B.A., Experienced Biotech Investor Relations and Strategy Executive, to Senior Vice President and Head, Investor Relations and Corporate Affairs (GlobeNewswire)
Jun-29-23 04:49PM	7 Up-and-Coming Stocks to Buy for the Next Decade (InvestorPlace)
Jun-22-23 04:00PM	Acrivon Therapeutics Announces the Appointment of Seasoned Biopharma Executive Charles Baum, M.D., Ph.D., a Recognized Leader in Clinical Precision Oncology, to its Board of Directors (GlobeNewswire) +5.98%
Jun-02-23 08:00AM	Acrivon Therapeutics to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-09-23 10:43AM	Q1 2023 Akoya Biosciences Inc Earnings Call (Thomson Reuters StreetEvents) +6.77%
08:00AM	Acrivon Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
08:00AM	Acrivon Therapeutics Announces FDA Grants Fast Track Designation for Development of ACR-368 in Platinum-Resistant Ovarian Cancer and Endometrial Cancer (GlobeNewswire)
May-07-23 08:17AM	We Think Acrivon Therapeutics (NASDAQ:ACRV) Can Afford To Drive Business Growth (Simply Wall St.)
Apr-25-23 08:00AM	Acrivon Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference (GlobeNewswire)
Apr-24-23 08:00AM	Acrivon Therapeutics to Host Virtual Investor Event on May 1, 2023 (GlobeNewswire)
Apr-18-23 08:00AM	Acrivon Therapeutics to Present at the Stifel 2023 Targeted Oncology Days Conference (GlobeNewswire)
Mar-28-23 08:00AM	Acrivon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights (GlobeNewswire)
Mar-06-23 08:00AM	Acrivon Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference (GlobeNewswire)
Feb-27-23 08:00AM	Acrivon Therapeutics to Participate on a Panel at Cowens 43rd Annual Health Care Conference (GlobeNewswire) +23.94%
Feb-15-23 05:40AM	Acrivon Therapeutics, Inc. (NASDAQ:ACRV) insider upped their holding earlier this year (Simply Wall St.)
Feb-14-23 10:15AM	2 Breakout Growth Stocks to Buy for the Long Haul (Motley Fool)
Jan-22-23 03:31PM	13 Cheap New Stocks To Buy (Insider Monkey)
Nov-14-22 10:16PM	Acrivon Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)

Acrivon Therapeutics, Inc. develops drugs for clinical treatment. Its unique precision medicine platform is Acrivon Predictive Precision Proteomics (AP3). AP3 is used to generate proprietary OncoSignature companion diagnostics to identify patients who will benefit from the medicine. The company was founded by Peter Blume-Jensen and Kristina Masson in 2018 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Blume-Jensen Peter	President and CEO	Jan 14 '26	Buy	1.68	49,000	82,124	2,095,771	Jan 16 04:02 PM
Levy Adam D.	Chief Financial Officer	Jan 14 '26	Buy	1.70	8,832	14,999	20,983	Jan 16 04:01 PM
Devroe Eric	Chief Operating Officer	Jan 13 '26	Buy	1.72	10,000	17,218	75,308	Jan 15 04:38 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Apr 30 '25	Sale	1.41	437,881	617,412	3,403,025	May 01 07:07 PM
PERCEPTIVE ADVISORS LLC	10% Owner	May 01 '25	Sale	1.34	298,886	400,507	3,104,139	May 01 07:07 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Apr 25 '25	Sale	1.95	1,054,669	2,056,605	4,306,189	Apr 29 07:26 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Apr 29 '25	Sale	1.41	250,000	352,500	3,840,906	Apr 29 07:26 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Apr 28 '25	Sale	1.56	215,283	335,841	4,090,906	Apr 29 07:26 PM

Open in Screener

ALDX

Aldeyra Therapeutics Inc

Feb 13 • 04:00PM ET

5.28

0.00 0.00 %

Healthcare • Biotechnology • USA • NASD

ALDX Aldeyra Therapeutics Inc daily Stock Chart

Peers: NBIX IONS XOMA PRTA CRBP ITCI BHVN AUPH ACAD RIGL

| Held by: VTI IWM VXF IWO VTWO VHT IWC VFMO PRFZ DFAS

Index	RUT	P/E	-	EPS (ttm)	-0.72	Insider Own	3.24%	Shs Outstand	60.16M	Perf Week	-4.52%
Market Cap	317.66M	Forward P/E	49.50	EPS next Y	0.11	Insider Trans	0.00%	Shs Float	55.66M	Perf Month	24.53%
Enterprise Value	257.90M	PEG	-	EPS next Q	-0.16	Inst Own	65.77%	Short Float	9.43%	Perf Quarter	-0.38%
Income	-43.19M	P/S	-	EPS this Y	34.89%	Inst Trans	13.29%	Short Ratio	4.98	Perf Half Y	-0.38%
Sales	0.00M	P/B	6.45	EPS next Y	117.43%	ROA	-44.27%	Short Interest	5.25M	Perf YTD	1.93%
Book/sh	0.82	P/C	4.22	EPS next 5Y	-	ROE	-64.31%	52W High	7.20 -26.67%	Perf Year	-18.39%
Cash/sh	1.25	P/FCF	-	EPS past 3/5Y	4.24% 15.99%	ROIC	-87.58%	52W Low	1.14 363.16%	Perf 3Y	-15.52%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.32% 7.18%	Perf 5Y	-58.43%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	4.23%	Oper. Margin	-	ATR (14)	0.35	Perf 10Y	35.38%
Dividend Ex-Date	-	Quick Ratio	2.68	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	53.59	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.68	EPS Q/Q	49.63%	SMA20	0.36%	Beta	0.97	Target Price	9.67
Payout	-	Debt/Eq	0.32	Sales Q/Q	-	SMA50	6.94%	Rel Volume	0.00	Prev Close	5.28
Employees	9	LT Debt/Eq	0.00	Earnings	Nov 13	SMA200	14.73%	Avg Volume	1.05M	Price	5.28
IPO	May 02, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	8.00% -	Trades		Volume	0	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-03-24	Upgrade	Oppenheimer	Perform → Outperform	$10
Apr-02-24	Resumed	H.C. Wainwright	Buy	$10
Apr-27-22	Resumed	H.C. Wainwright	Buy	$15
Feb-08-21	Initiated	H.C. Wainwright	Buy	$26
Dec-16-20	Initiated	Berenberg	Buy	$32
Oct-30-20	Initiated	Jefferies	Buy	$24
Oct-16-20	Initiated	BTIG Research	Buy	$29
Sep-22-20	Initiated	Alliance Global Partners	Buy	$32
May-12-20	Initiated	Oppenheimer	Outperform	$12
Dec-04-18	Initiated	Citigroup	Buy	$23
Sep-26-18	Reiterated	Cantor Fitzgerald	Overweight	$23 → $30
Sep-13-18	Initiated	Janney	Buy
Jan-26-18	Initiated	Seaport Global Securities	Buy	$13
Sep-26-16	Initiated	H.C. Wainwright	Buy	$18
Jul-01-16	Initiated	Stifel	Buy	$16
Jul-01-15	Initiated	Canaccord Genuity	Buy	$16
Mar-25-15	Initiated	Chardan Capital Markets	Buy	$16
Mar-20-15	Reiterated	H.C. Wainwright	Buy	$13 → $14
Nov-18-14	Initiated	H.C. Wainwright	Buy	$13
Jun-19-14	Initiated	Aegis Capital	Buy	$35

Show Previous Ratings

Feb-03-26 09:55AM	Wall Street Analysts Predict a 65.75% Upside in Aldeyra Therapeutics (ALDX): Here's What You Should Know (Zacks)
09:40AM	Are Medical Stocks Lagging Aldeyra Therapeutics (ALDX) This Year? (Zacks)
Dec-15-25 07:30PM	Aldeyra Therapeutics Announces PDUFA Extension of the New Drug Application of Reproxalap for the Treatment of Dry Eye Disease (Business Wire) -12.11% +33.08%
Nov-13-25 07:00AM	Aldeyra Therapeutics Announces Expansion of RASP Platform to Include Central Nervous System Diseases and Provides Updates on Reproxalap at Research & Development Webcast (Business Wire) -5.28%
Nov-11-25 07:01AM	Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London (Business Wire)
07:00AM	Loading…
Nov-06-25 07:00AM	Aldeyra Therapeutics to Host Research & Development Update Webcast Event Scheduled for Thursday, November 13 at 8:00 a.m. ET (Business Wire)
Oct-29-25 08:16AM	Aldeyra reshuffles pipeline, culling asset despite Phase II success (Clinical Trials Arena)
Oct-28-25 07:01AM	Aldeyra Therapeutics Announces Positive Results from Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses RASP Product Candidate Pipeline on Next-Generation Molecules (Business Wire)
Sep-03-25 07:01AM	Aldeyra Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference (Business Wire)
Aug-28-25 07:01AM	Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Primary Large B-Cell Lymphomas of Immune-Privileged Sites, including Primary Vitreoretinal Lymphoma (Business Wire)
Aug-23-25 04:20AM	JonesTrading Lifts Aldeyra Therapeutics, Inc. (ALDX) Price Target to $9 (Insider Monkey)
Aug-19-25 07:01AM	Aldeyra Therapeutics Receives Fast Track Designation for ADX-2191 for the Treatment of Retinitis Pigmentosa (Business Wire)
Aug-06-25 07:01AM	Aldeyra Therapeutics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference (Business Wire)
Jul-24-25 07:00AM	Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Inherited Retinal Dystrophies including Retinitis Pigmentosa (Business Wire)
Jul-17-25 09:11AM	Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics (Zacks)
07:00AM	Loading…
07:00AM	Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease (Business Wire)
Jul-16-25 09:01AM	5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats (Zacks)
Jul-15-25 12:00PM	Aldeyra Therapeutics (ALDX) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks)
09:40AM	Are Medical Stocks Lagging Amgen (AMGN) This Year? (Zacks)
Jun-26-25 07:00AM	Aldeyra Therapeutics Receives Special Protocol Assessment Agreement Letter from the U.S. Food and Drug Administration for ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma (Business Wire) +10.26%
Jun-17-25 07:00AM	Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease (Business Wire)
May-29-25 07:01AM	Aldeyra Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference (Business Wire)
May-05-25 06:34PM	Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of Reproxalap and Plans NDA Resubmission (Business Wire) -22.22%
04:00PM	Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Topline Results from Phase 3 Dry Eye Disease Clinical Trials of Reproxalap (Business Wire)
Apr-29-25 11:42AM	Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter Hagens Berman (GlobeNewswire)
Apr-28-25 09:00PM	Bragar Eagel & Squire, P.C. Is Investigating TechTarget and Aldeyra and Encourages Investors to Contact the Firm (GlobeNewswire)
Apr-24-25 01:57PM	Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter Hagens Berman (GlobeNewswire) +9.50%
Apr-21-25 09:00PM	Bragar Eagel & Squire, P.C. Is Investigating TechTarget and Aldeyra and Encourages Investors to Contact the Firm (GlobeNewswire)
10:52AM	Aldeyra Therapeutics: A Mispriced Gem With Reproxalap's CRL Creating A Golden Buying Opportunity (Seeking Alpha)
08:49AM	Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter Hagens Berman (GlobeNewswire)
02:52PM	Loading…
Apr-18-25 02:52PM	Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter Hagens Berman (GlobeNewswire)
11:23AM	ALDX INVESTOR NOTICE: Aldeyra Therapeutics, Inc. Investors are Notified to Contact BFA Law About How to Potentially Recover Losses (Newsfile)
Apr-17-25 07:00AM	Aldeyra Therapeutics Appoints Chip Clark to Board of Directors (Business Wire) +8.96%
Apr-16-25 05:23PM	Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter Hagens Berman (GlobeNewswire) -8.64%
Apr-15-25 09:00PM	Bragar Eagel & Squire, P.C. Is Investigating TechTarget and Aldeyra and Encourages Investors to Contact the Firm (GlobeNewswire)
Apr-11-25 01:26PM	Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter Hagens Berman (GlobeNewswire)
07:43AM	ALDX STOCK NOTIFICATION: Did Aldeyra Therapeutics, Inc. Violate the Securities Laws? Investors are Notified to Contact BFA Law (NASDAQ:ALDX) (GlobeNewswire)
Apr-10-25 09:30AM	Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter - Hagens Berman (PR Newswire)
Apr-09-25 05:00PM	Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter Hagens Berman (GlobeNewswire)
Apr-08-25 04:51AM	After A CRL Setback, Aldeyra Therapeutics Is A Compelling Speculative Buy (Seeking Alpha)
03:08AM	ALDX SECURITIES NOTIFICATION: Aldeyra Therapeutics, Inc. Investors that Suffered Losses are Notified to Contact BFA Law (Newsfile)
Apr-06-25 07:08AM	ALDX SECURITIES NOTICE: Aldeyra Therapeutics, Inc. Investors with Losses are Notified to Contact BFA Law as they may have been Affected by Securities Violations (Newsfile)
Apr-03-25 10:24AM	Aldeyra Therapeutics Stock Craters to All-Time Low on FDA Letter (Investopedia) -73.33%
08:00AM	Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease (Business Wire)
Mar-10-25 07:00AM	Aldeyra Therapeutics to Participate in the 2025 Leerink Partners Global Healthcare Conference (Business Wire)
Feb-05-25 03:24AM	Aldeyra Therapeutics, Inc. (ALDX) Notice: Grabar Law Office Is Investigating Claims for Long-Term Shareholders (Newsfile) +6.73%
Feb-04-25 07:00AM	Aldeyra Therapeutics to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference (Business Wire)
Jan-20-25 03:28PM	Is Aldeyra Therapeutics (ALDX) Among Billionaire Joseph Edelman's Long-Term Stock Picks? (Insider Monkey)
Dec-09-24 10:05AM	Is the Options Market Predicting a Spike in Aldeyra Therapeutics (ALDX) Stock? (Zacks)
Dec-02-24 07:00AM	Aldeyra Therapeutics to Participate in the Citi 2024 Global Healthcare Conference (Business Wire)
Nov-18-24 07:00AM	Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease, Expands AbbVie Option Agreement (Business Wire) +11.64%
Nov-14-24 07:00AM	Aldeyra Therapeutics to Participate in the Jefferies London Healthcare Conference (Business Wire)
Oct-31-24 07:00AM	Aldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 Meeting (Business Wire)
Oct-03-24 07:00AM	Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease (Business Wire)
Sep-05-24 07:00AM	Aldeyra Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference (Business Wire)
Aug-30-24 10:38AM	Aldeyra Therapeutics Inc (NASDAQ:ALDX) A Bull Case Theory (Insider Monkey) +7.07%
Aug-09-24 06:32AM	Aldeyras Phase III clinical trial of Reproxalap meets primary endpoint (Clinical Trials Arena) +21.72%
Aug-08-24 07:00AM	Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap (Business Wire) +28.53%
Aug-07-24 04:01PM	Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 Dry Eye Chamber Clinical Trial of Reproxalap (Business Wire) -5.23%
Jun-20-24 07:00AM	Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable (Business Wire) -6.47%
Jun-14-24 06:32AM	Aldeyra Therapeutics concludes subject enrolment in dry eye disease trial (Clinical Trials Arena)
Jun-13-24 07:00AM	Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease (Business Wire)
Jun-12-24 07:00AM	Aldeyra Therapeutics to Host Investor Roundtable Q&A (Business Wire)
May-29-24 07:00AM	Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference (Business Wire)
May-14-24 09:40AM	Is Aldeyra Therapeutics (ALDX) Stock Outpacing Its Medical Peers This Year? (Zacks) +12.70%
May-08-24 03:12PM	Aldeyra Therapeutics Enrolls First Patient in Phase 3 Dry Eye Chamber Study (MT Newswires)
07:00AM	Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease (Business Wire)
May-03-24 08:52AM	ALDX Stock Earnings: Aldeyra Therapeutics Meets EPS for Q1 2024 (InvestorPlace)
Apr-25-24 07:00AM	Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day (Business Wire)
Apr-22-24 09:40AM	Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year? (Zacks)
Apr-18-24 07:00AM	Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024 (Business Wire)
Apr-06-24 06:37AM	Aldeyra (ALDX) Stock Rallies 43% in One Week: Here's Why (Zacks)
Apr-04-24 12:36PM	Health Care Roundup: Market Talk (The Wall Street Journal) +12.89%
Apr-03-24 02:58PM	Aldeyra's Dry Eye Disease Drug May Be on Path for FDA Approval (Barrons.com) +16.90%
Mar-28-24 07:00AM	Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease (Business Wire) +6.17%
Mar-27-24 01:21PM	Notice to Long-Term Aldeyra Therapeutics, Inc. (ALDX) Investors (Newsfile) +5.48%
Mar-13-24 02:33AM	Aldeyra Therapeutics Inc President and CEO Todd Brady Sells Company Shares (GuruFocus.com)
Mar-06-24 09:40AM	Here's Why You Should Invest in Aldeyra (ALDX) Stock Now (Zacks)
Feb-06-24 07:00AM	Aldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference (Business Wire) +7.05%
Jan-04-24 07:00AM	Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory Diseases (Business Wire)
Dec-19-23 07:27AM	UPDATE 1-Aldeyra Therapeutics' skin disease drug succeeds in mid-stage study (Reuters) +18.58%
07:05AM	Aldeyra Therapeutics' eczema drug succeeds in mid-stage study (Reuters)
07:00AM	Aldeyra Therapeutics Announces Statistically and Clinically Significant Improvement from Baseline in Phase 2 Clinical Trial of ADX629 in Patients with Atopic Dermatitis (Business Wire)
Dec-18-23 04:01PM	Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis (Business Wire)
Dec-06-23 11:55AM	13 Hot Penny Stocks To Buy According to Hedge Funds (Insider Monkey)
Dec-05-23 09:00AM	Should You Buy Aldeyra Therapeutics (ALDX) Ahead of Earnings? (Zacks)
Nov-27-23 04:07PM	Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease (Business Wire)
Nov-01-23 10:34AM	Why Is Aldeyra Therapeutics (ALDX) Stock Up 40% Today? (InvestorPlace) +48.54%
07:05AM	Aldeyra Therapeutics Enters into Exclusive Option Agreement with AbbVie for License to Develop and Commercialize Reproxalap (Business Wire)
Oct-18-23 08:30AM	Biotech Stock Roundup: ALDX, EVLO Down on Setback, SRRK Offers Updates & More (Zacks) -5.98%
Oct-17-23 10:13AM	Aldeyra (ALDX) Plummets on Dry Eye Disease Drug's Setback (Zacks)
Aug-28-23 10:22AM	15 Most Shorted Stocks That Are Loved By Analysts (Insider Monkey)
Jul-20-23 09:55AM	Can Aldeyra Therapeutics, Inc. (ALDX) Climb 107.66% to Reach the Level Wall Street Analysts Expect? (Zacks)
Jul-06-23 07:00AM	Aldeyra Therapeutics to Participate in SVB Securities Therapeutics Forum (Business Wire)
Jun-29-23 07:00AM	Aldeyra Therapeutics Announces Improvement from Baseline in Retinal Function in Phase 2 Clinical Trial of ADX2191 in Patients with Retinitis Pigmentosa (Business Wire)
05:20AM	The Petri Dish: Startup behind VR treatments gets $16M, Aldeyra notches midstage trial win (American City Business Journals)
Jun-28-23 04:01PM	Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 2 Clinical Trial of ADX-2191 in Patients with Retinitis Pigmentosa (Business Wire)
Jun-27-23 12:03PM	Aldeyra Therapeutics' Chronic Cough Potential Shows Significant Reduction In Cough Frequency Versus Placebo (Benzinga)
07:00AM	Aldeyra Therapeutics Announces Statistically Significant Reduction in Cough Frequency in Phase 2 Clinical Trial of ADX629 in Patients With Chronic Cough (Business Wire)
Jun-26-23 04:01PM	Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 2 Clinical Trial of ADX629 in Patients with Chronic Cough (Business Wire) +5.63%

Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities with related general business planning, including raising capital. It engages in the discovery of therapies designed to treat immune-mediated diseases. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Alfieri Michael	Principal Financial Officer	Aug 13 '25	Buy	5.30	2,500	13,250	2,500	Aug 15 04:09 PM
Machatha Stephen	Chief Development Officer	Aug 11 '25	Sale	5.15	22,073	113,713	221,799	Aug 13 06:03 PM
Machatha Stephen	Officer	Aug 12 '25	Proposed Sale	5.26	22,074	116,109		Aug 12 05:50 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Apr 03 '25	Sale	1.42	3,400,000	4,828,000	5,875,851	Apr 07 06:43 PM

Open in Screener

SLDB

Solid Biosciences Inc

Feb 13 • 04:00PM ET

6.19

0.00 0.00 %

Healthcare • Biotechnology • USA • NASD

SLDB Solid Biosciences Inc daily Stock Chart

Peers: SRPT PFE BMRN BLUE QURE EDIT RGEN NTLA ABEO VYGR

| Held by: VTI IWM IWN VXF IBB VTWO DFAS IWC PRFZ AVSC

Index	RUT	P/E	-	EPS (ttm)	-2.49	Insider Own	25.12%	Shs Outstand	77.88M	Perf Week	-5.06%
Market Cap	482.26M	Forward P/E	-	EPS next Y	-2.04	Insider Trans	-1.94%	Shs Float	58.46M	Perf Month	6.54%
Enterprise Value	268.06M	PEG	-	EPS next Q	-0.50	Inst Own	81.74%	Short Float	14.81%	Perf Quarter	30.59%
Income	-167.13M	P/S	-	EPS this Y	31.42%	Inst Trans	3.40%	Short Ratio	8.21	Perf Half Y	0.32%
Sales	0.00M	P/B	2.21	EPS next Y	2.96%	ROA	-68.82%	Short Interest	8.66M	Perf YTD	9.75%
Book/sh	2.80	P/C	2.04	EPS next 5Y	14.41%	ROE	-86.83%	52W High	7.37 -16.01%	Perf Year	57.11%
Cash/sh	3.03	P/FCF	-	EPS past 3/5Y	32.97% 41.25%	ROIC	-70.35%	52W Low	2.41 156.85%	Perf 3Y	-11.82%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	11.40% 7.31%	Perf 5Y	-94.68%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	17.88%	Oper. Margin	-	ATR (14)	0.46	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.74	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	49.39	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	6.74	EPS Q/Q	38.60%	SMA20	-3.31%	Beta	2.64	Target Price	15.75
Payout	-	Debt/Eq	0.10	Sales Q/Q	-	SMA50	4.16%	Rel Volume	0.00	Prev Close	6.19
Employees	100	LT Debt/Eq	0.09	Earnings	Nov 03 AMC	SMA200	16.63%	Avg Volume	1.05M	Price	6.19
IPO	Jan 26, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	-9.34% -	Trades		Volume	0	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-04-25	Initiated	Needham	Buy	$16
Jun-26-25	Initiated	Citigroup	Buy	$14
Jan-08-25	Initiated	Truist	Buy	$16
Dec-13-24	Initiated	Wedbush	Outperform	$16
Dec-10-24	Initiated	JMP Securities	Mkt Outperform	$15
Jul-15-24	Upgrade	JP Morgan	Neutral → Overweight	$10 → $15
Jun-24-24	Upgrade	Leerink Partners	Market Perform → Outperform	$12
May-31-24	Resumed	Piper Sandler	Overweight	$20
Mar-28-24	Initiated	William Blair	Outperform	$40
Mar-15-24	Initiated	Citigroup	Buy	$16
Mar-14-24	Upgrade	Piper Sandler	Neutral → Overweight	$8 → $20
Dec-08-23	Initiated	H.C. Wainwright	Buy	$9
Jul-12-21	Initiated	Piper Sandler	Neutral	$6
May-27-21	Initiated	Jefferies	Buy	$7
Mar-16-21	Upgrade	SVB Leerink	Mkt Perform → Outperform	$3 → $15
Mar-09-21	Initiated	Barclays	Overweight	$13
Jan-08-21	Upgrade	Credit Suisse	Underperform → Neutral	$2 → $7
Jul-28-20	Downgrade	SVB Leerink	Outperform → Mkt Perform
May-07-20	Downgrade	Evercore ISI	Outperform → In-line
Oct-11-19	Initiated	Evercore ISI	Outperform	$22

Show Previous Ratings

Feb-15-26 05:35AM	Solid Biosciences Highlights FDA Path for SGT-003 DMD Study, Shares Early Friedreichs Ataxia Update (MarketBeat)
Feb-09-26 08:00AM	Solid Biosciences Announces Positive Feedback from Type C Meeting with FDA for SGT-003 Gene Therapy for Duchenne Muscular Dystrophy (GlobeNewswire) +5.21%
Feb-06-26 08:00AM	Solid Biosciences to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire)
Jan-26-26 02:49PM	Sarepta Stock Climbs. 3-Year Study Results for Elevidys Bring Hope. (Barrons.com)
Jan-16-26 09:08AM	Will KROS Stock's Restructuring Efforts Reap Rewards for Investors? (Zacks)
12:58PM	Loading…
Jan-15-26 12:58PM	JPM26: Solid Biosciences banks on its AAV capsid to catalyse gene therapy success (Pharmaceutical Technology)
Jan-13-26 04:15PM	Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101 (GlobeNewswire) +12.60%
Jan-12-26 04:15PM	Solid Biosciences Receives FDA Orphan Drug Designation for SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich's Ataxia (GlobeNewswire)
08:05AM	Solid Biosciences Doses First Participant in First-in-Class Phase 1b FALCON Trial Evaluating SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich's Ataxia (GlobeNewswire)
Jan-06-26 08:00AM	Solid Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-05-26 04:15PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-16-25 04:51PM	Solid Biosciences Announces Duchenne Muscular Dystrophy Added to National Recommended Uniform Screening Panel by the U.S. Department of Health and Human Services (GlobeNewswire) -7.56%
Dec-15-25 11:10PM	Sarepta's Elevidys Safety Concerns Open Major Opportunity for Solid Biosciences' (SLDB) SGT-003 in Duchenne Therapy (Insider Monkey)
Dec-08-25 08:00AM	Solid Biosciences to Showcase Proprietary Next-Generation Capsid AAV-SLB101 and Cardiac Gene Therapy Pipeline at the 22nd Global CardioVascular Clinical Trialists (CVCT) Forum (GlobeNewswire)
Dec-02-25 06:54AM	Solid Biosciences' SGT-212 gains FDA rare paediatric disease status (Pharmaceutical Business Review)
04:05PM	Loading…
Dec-01-25 04:05PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Solid Biosciences Receives FDA Rare Pediatric Disease Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich's Ataxia (GlobeNewswire)
Nov-17-25 08:00AM	Solid Biosciences Announces Licensing Agreement with Andelyn Biosciences for the Use of Proprietary Next-Generation Capsid AAV-SLB101 (GlobeNewswire)
Nov-11-25 08:00AM	Solid Biosciences to Participate at Upcoming Investor Conferences (GlobeNewswire) +9.16%
Nov-06-25 08:00AM	Solid Biosciences Awarded Innovation Passport Designation Under the New UK Innovative Licensing and Access Pathway for SGT-003, an Investigational Gene Therapy for Duchenne Muscular Dystrophy (GlobeNewswire) +7.25%
Nov-04-25 04:05PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -15.29% -10.78%
Nov-03-25 04:05PM	Solid Biosciences Reports Third Quarter 2025 Financial Results and Provides Update on INSPIRE DUCHENNE Clinical Trial Progress and Planned Regulatory Discussions (GlobeNewswire)
Oct-30-25 08:00AM	Solid Biosciences to Participate at Upcoming Investor Conferences (GlobeNewswire)
Oct-01-25 04:05PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Solid Biosciences to Present at Upcoming Scientific Meetings (GlobeNewswire)
Sep-25-25 08:00AM	Solid Biosciences to Present at 2025 Neuromuscular Study Group Annual Scientific Meeting (GlobeNewswire) -5.13%
Sep-23-25 08:00AM	Solid Biosciences Announces Licensing Agreement with Kinea Bio for the Use of Proprietary Next-Generation Capsid AAV-SLB101 (GlobeNewswire)
Sep-18-25 09:10AM	Anti-Aging Biotech Surges as $101M Competition Ignites Global Race Against Aging Demographics (PR Newswire)
Aug-28-25 08:00AM	Solid Biosciences to Participate at Upcoming Investor Conferences (GlobeNewswire)
Aug-12-25 04:07PM	Solid Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire) +10.60%
03:33PM	Loading…
03:33PM	Brutal 2025 for Sarepta-Analysts Still Call for 179% Upside (MarketBeat)
Aug-01-25 08:00AM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-23-25 08:00AM	Solid Biosciences Receives FDA Fast Track Designation for SGT-501 First-in-Class Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) (GlobeNewswire) +8.51%
Jul-21-25 08:30AM	Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors (GlobeNewswire)
Jul-09-25 10:17AM	Citi Initiates Coverage on Solid Biosciences Inc. (SLDB) with 'Buy' Rating and $14 PT (Insider Monkey) +5.34%
Jul-08-25 04:05PM	Solid Biosciences Announces FDA IND and Health Canada CTA Approval for First-in-Class Cardiac Gene Therapy to Treat Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) (GlobeNewswire) +6.72%
Jul-01-25 04:05PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.54% +5.87%
Jun-26-25 09:49AM	General Mills upgraded, Trade Desk downgraded: Wall Street's top analyst calls (The Fly)
Jun-18-25 11:39AM	Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences (MarketBeat)
Jun-03-25 08:00AM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-28-25 08:00AM	Solid Biosciences to Participate at the Jefferies Global Healthcare Conference (GlobeNewswire) +7.24%
May-15-25 04:06PM	Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire) +6.95%
May-01-25 04:00PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +10.27% +18.08%
Apr-30-25 08:00AM	Solid Biosciences to Participate at The Citizens Life Sciences Conference (GlobeNewswire) +8.52%
Apr-29-25 08:00AM	Solid Biosciences to Present at the American Society of Gene and Cell Therapy's 28th Annual Meeting (GlobeNewswire) -5.57%
Apr-08-25 04:50PM	Solid Biosciences: A Strong Buy As An Emerging Biotech In The Gene Therapy Space (Seeking Alpha) -9.18%
07:30AM	Can Solid Biosciences Challenge Sarepta in the DMD Market? (MarketBeat)
Apr-07-25 08:00AM	Solid Biosciences to Participate at Upcoming Investor Conferences (GlobeNewswire) -5.62%
Apr-01-25 08:00AM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.89%
07:00AM	Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors (GlobeNewswire)
Mar-26-25 12:31PM	5 Reasons To Buy Regenxbio Right Now (SeekingAlpha) -5.12%
Mar-14-25 10:29PM	Solid Biosciences Inc. (SLDB): Among Top Insider Purchases Last Month (Insider Monkey) +5.30%
Mar-12-25 08:00AM	Solid Biosciences to Present at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference (GlobeNewswire)
Mar-07-25 09:55AM	Wall Street Analysts Believe Solid Biosciences (SLDB) Could Rally 198.18%: Here's is How to Trade (Zacks)
Mar-06-25 04:16PM	Solid Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-05-25 08:00AM	Solid Biosciences to Participate at Upcoming Investor Conferences (GlobeNewswire) +8.47%
Mar-04-25 08:33PM	Is Solid Biosciences Inc. (SLDB) Among Stocks With At Least $20 Million In Insider Spending Recently? (Insider Monkey)
04:07PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-19-25 08:02AM	Solid Biosciences stock soars on early success in DMD gene therapy trial (Clinical Trials Arena) +22.08%
Feb-18-25 07:00AM	Solid Biosciences Announces Pricing of Underwritten Offering (GlobeNewswire) +31.51%
06:45AM	Solid Biosciences Reports Positive Initial Clinical Data from Next-Generation Duchenne Gene Therapy Candidate SGT-003 (GlobeNewswire)
06:36AM	Solid says early data suggest differentiated Duchenne gene therapy (BioPharma Dive)
Feb-09-25 06:12AM	Analysts Predict Up to ~450% Surge for These 2 Strong Buy Penny Stocks (TipRanks)
Feb-04-25 08:00AM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-21-25 08:30AM	Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich's Ataxia (GlobeNewswire)
Jan-15-25 04:05PM	Solid Biosciences Outlines Key Priorities for Advancing Diversified Neuromuscular and Cardiac Development Pipeline and Establishing Leadership in Precision Genetic Medicines (GlobeNewswire)
Jan-08-25 04:05PM	Solid Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -8.68%
Jan-07-25 04:15PM	Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich's Ataxia (GlobeNewswire)
Jan-06-25 08:00AM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-23-24 04:05PM	Solid Biosciences Added to the Nasdaq Biotechnology Index (GlobeNewswire)
Dec-13-24 01:52PM	Solid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy Treatment Success: Analyst (Benzinga)
Dec-04-24 08:05AM	Solid Biosciences reports inducement grant under Nasdaq listing rule (TipRanks)
08:00AM	Solid Biosciences Announces Collaboration with Mayo Clinic to Accelerate Gene Therapy Innovation and Advance Development of Cardiac Gene Therapies (GlobeNewswire)
Dec-03-24 08:00AM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -10.54%
Nov-26-24 08:00AM	Solid Biosciences to Participate at Upcoming Investor Conferences (GlobeNewswire)
Nov-14-24 08:00AM	Solid Biosciences to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Nov-06-24 04:05PM	Solid Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) -6.03%
Nov-04-24 08:00AM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-31-24 08:00AM	Solid Biosciences to Participate at the Truist Securities BioPharma Symposium (GlobeNewswire)
Oct-02-24 04:15PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-23-24 08:00AM	Solid Biosciences to Participate at Chardan's 8th Annual Genetic Medicines Conference (GlobeNewswire)
Sep-12-24 08:00AM	Solid Biosciences to Participate at the 2024 Cantor Global Healthcare Conference (GlobeNewswire)
Sep-04-24 04:05PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Solid Biosciences to Participate at Upcoming Investor Conferences (GlobeNewswire)
Aug-13-24 04:08PM	Solid Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) +14.54%
Aug-05-24 08:00AM	Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-01-24 04:19PM	Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +10.58%
08:00AM	Solid Biosciences Joins the Russell 3000 Index (GlobeNewswire)
Jun-21-24 07:52AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
Jun-04-24 04:00PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-20-24 06:00AM	3 Must-Buy Biotech Stocks Before the Summer Rally Kicks Off (InvestorPlace)
May-15-24 12:53PM	SLDB Stock Earnings: Solid Biosciences Meets EPS for Q1 2024 (InvestorPlace)
07:52AM	Solid Biosciences Provides First Quarter 2024 Business Update and Financial Results (GlobeNewswire)
May-07-24 07:00AM	Solid Biosciences to Present at the American Society of Gene and Cell Therapy Annual Meeting (GlobeNewswire)
May-02-24 04:05PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.23%
Apr-03-24 04:05PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-02-24 10:35AM	Solid Biosciences (SLDB) Falls Despite FDA Rare Tag for DMD Drug (Zacks)
07:20AM	Solid Biosciences' SGT-003 receives rare pediatric disease designation (Pharmaceutical Business Review)
Apr-01-24 07:45AM	Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003 (GlobeNewswire) -6.61%
Mar-28-24 04:08PM	How Sleeper Biotech Solid Biosciences, With A 687% Gain, Is Making A Comeback (Investor's Business Daily) -6.53%

Solid Biosciences, Inc. is a life science company, which engages in the development of treatments for patients with Duchenne muscular dystrophy. It also focuses on developing treatments for neuromuscular and cardiac diseases. The company was founded by Ilan Ganot, Andrey J. Zarur, Matthew Bennett Arnold, Annie Ganot, and Gilad David Hayeem in March 2013 and is headquartered in Charlestown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Howton David T	Chief Operating Officer	Feb 04 '26	Sale	6.44	18,894	121,713	97,859	Feb 06 06:05 PM
Cumbo Alexander	President and CEO	Feb 04 '26	Sale	6.44	48,913	315,093	222,018	Feb 06 06:01 PM
Ganot Ilan	Director	Feb 04 '26	Sale	6.44	7,205	46,414	25,271	Feb 06 06:01 PM
Tan Kevin	CFO & Treasurer	Feb 04 '26	Sale	6.44	14,783	95,231	94,201	Feb 06 06:00 PM
Brooks Gabriel	Chief Medical Officer	Feb 04 '26	Sale	6.44	12,616	81,271	84,092	Feb 06 05:59 PM
Hanrahan Jessie	Chief Regulatory Officer	Feb 04 '26	Sale	6.44	12,348	79,545	70,327	Feb 06 05:57 PM
Herzich Paul	Chief Technology Officer	Feb 04 '26	Sale	6.44	10,905	70,249	69,067	Feb 06 05:56 PM
Tan Kevin	Officer	Feb 04 '26	Proposed Sale	6.44	14,783	95,227		Feb 04 07:48 PM
Herzich Paul	Officer	Feb 04 '26	Proposed Sale	6.44	10,905	70,247		Feb 04 07:46 PM
Ganot Ilan	Director	Feb 04 '26	Proposed Sale	6.44	7,205	46,412		Feb 04 07:45 PM
Cumbo Alexander	Officer	Feb 04 '26	Proposed Sale	6.44	48,913	315,080		Feb 04 07:44 PM
Howton David T	Officer	Feb 04 '26	Proposed Sale	6.44	18,894	121,708		Feb 04 07:42 PM
Hanrahan Jessie	Officer	Feb 04 '26	Proposed Sale	6.44	12,348	79,541		Feb 04 07:40 PM
Brooks Gabriel	Officer	Feb 04 '26	Proposed Sale	6.44	12,616	81,268		Feb 04 07:37 PM
Tan Kevin	CFO & Treasurer	Feb 02 '26	Sale	6.44	26,837	172,747	108,984	Feb 02 08:18 PM
Cumbo Alexander	President and CEO	Feb 02 '26	Sale	6.44	80,258	516,613	270,931	Feb 02 08:16 PM
Hanrahan Jessie	Chief Regulatory Officer	Feb 02 '26	Sale	6.44	26,535	170,803	82,675	Feb 02 08:15 PM
Brooks Gabriel	Chief Medical Officer	Feb 02 '26	Sale	6.44	28,335	182,390	96,708	Feb 02 08:14 PM
Howton David T	Chief Operating Officer	Feb 02 '26	Sale	6.44	37,771	243,128	116,753	Feb 02 08:12 PM
Herzich Paul	Chief Technology Officer	Feb 02 '26	Sale	6.44	26,250	168,969	79,972	Feb 02 08:09 PM
Hanrahan Jessie	Officer	Feb 02 '26	Proposed Sale	6.44	26,535	170,803		Feb 02 08:07 PM
Brooks Gabriel	Officer	Feb 02 '26	Proposed Sale	6.44	28,335	182,390		Feb 02 08:05 PM
Tan Kevin	Officer	Feb 02 '26	Proposed Sale	6.44	26,837	172,747		Feb 02 08:04 PM
Cumbo Alexander	Officer	Feb 02 '26	Proposed Sale	6.44	80,258	516,613		Feb 02 08:03 PM
Howton David T	Officer	Feb 02 '26	Proposed Sale	6.44	37,771	243,128		Feb 02 08:01 PM
Herzich Paul	Officer	Feb 02 '26	Proposed Sale	6.44	26,250	168,969		Feb 02 07:59 PM
Ganot Ilan	Director	Jan 28 '26	Sale	6.59	191	1,259	17,476	Jan 30 04:05 PM
Tan Kevin	CFO & Treasurer	Jan 13 '26	Sale	5.27	5,704	30,060	46,100	Jan 13 05:02 PM
Tan Kevin	Officer	Jan 13 '26	Proposed Sale	5.27	5,704	30,060		Jan 13 05:00 PM
Ganot Ilan	Director	Jan 05 '26	Sale	5.43	1,053	5,718	17,278	Jan 06 06:52 PM
Howton David T	Chief Operating Officer	Dec 03 '25	Sale	5.11	4,932	25,203	32,908	Dec 04 04:22 PM
Cumbo Alexander	President and CEO	Dec 03 '25	Sale	5.11	10,808	55,229	81,388	Dec 04 04:20 PM
Hanrahan Jessie	Chief Regulatory Officer	Dec 03 '25	Sale	5.11	4,483	22,908	26,660	Dec 04 04:19 PM
Herzich Paul	Chief Technology Officer	Dec 03 '25	Sale	5.11	2,701	13,802	26,622	Dec 04 04:17 PM
Cumbo Alexander	Officer	Dec 03 '25	Proposed Sale	5.11	10,808	55,229		Dec 03 05:07 PM
Ganot Ilan	Director	Nov 10 '25	Sale	4.12	3,278	13,505	95,412	Nov 13 04:05 PM
Brooks Gabriel	Chief Medical Officer	Oct 20 '25	Sale	5.96	2,895	17,254	33,819	Oct 21 04:05 PM
Kahn Clare	Director	Mar 11 '25	Buy	5.34	1,860	9,924	2,960	Mar 13 04:05 PM
Bain Capital Life Sciences Inv	10% Owner	Feb 19 '25	Buy	4.03	1,000,000	4,030,000	5,034,582	Feb 21 05:48 PM
PERCEPTIVE ADVISORS LLC	Director	Feb 19 '25	Buy	4.03	5,000,000	20,150,000	11,833,539	Feb 21 04:17 PM
Adage Capital Management, L.P.	10% Owner	Feb 18 '25	Buy	7.56	252,545	1,909,240	4,248,084	Feb 19 04:16 PM

Open in Screener

MGTX

MeiraGTx Holdings plc

Feb 13 • 04:00PM ET

7.45

0.00 0.00 %

Healthcare • Biotechnology • USA • NASD

MGTX MeiraGTx Holdings plc daily Stock Chart

Peers: SRPT BLUE AGIO EPIX CLLS BNTX ADVM ALLO EDIT CRSP

| Held by: IWM IBB IWO VTWO VHT IWC IWN PRFZ VFMO VTWG

Index	RUT	P/E	-	EPS (ttm)	-2.11	Insider Own	28.10%	Shs Outstand	80.48M	Perf Week	0.27%
Market Cap	599.66M	Forward P/E	-	EPS next Y	-1.13	Insider Trans	-0.32%	Shs Float	57.87M	Perf Month	0.00%
Enterprise Value	672.88M	PEG	-	EPS next Q	-0.57	Inst Own	58.40%	Short Float	9.42%	Perf Quarter	-13.97%
Income	-168.69M	P/S	21.87	EPS this Y	19.93%	Inst Trans	6.05%	Short Ratio	11.22	Perf Half Y	-10.56%
Sales	27.42M	P/B	-	EPS next Y	33.52%	ROA	-69.00%	Short Interest	5.45M	Perf YTD	-6.29%
Book/sh	-0.50	P/C	40.41	EPS next 5Y	27.24%	ROE	-611.42%	52W High	9.73 -23.43%	Perf Year	12.88%
Cash/sh	0.18	P/FCF	-	EPS past 3/5Y	-5.50% -5.10%	ROIC	-	52W Low	4.55 63.74%	Perf 3Y	-6.05%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-4.07% 20.15%	Gross Margin	-4.57%	Volatility	5.14% 5.50%	Perf 5Y	-51.84%
Dividend TTM	-	EV/Sales	24.54	EPS Y/Y TTM	-61.92%	Oper. Margin	-597.91%	ATR (14)	0.42	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.22	Sales Y/Y TTM	96.83%	Profit Margin	-615.27%	RSI (14)	45.62	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.22	EPS Q/Q	-13.66%	SMA20	-2.99%	Beta	1.38	Target Price	26.75
Payout	-	Debt/Eq	-	Sales Q/Q	-96.24%	SMA50	-5.65%	Rel Volume	0.00	Prev Close	7.45
Employees	381	LT Debt/Eq	-	Earnings	Nov 13 BMO	SMA200	-1.65%	Avg Volume	485.83K	Price	7.45
IPO	Jun 08, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	-26.53% -94.11%	Trades		Volume	0	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-24-25	Initiated	H.C. Wainwright	Buy	$20
Oct-21-25	Initiated	Raymond James	Strong Buy	$29
Jul-31-24	Resumed	Chardan Capital Markets	Buy	$36
Oct-23-20	Initiated	RBC Capital Mkts	Outperform	$27
Sep-15-20	Resumed	BofA Securities	Buy	$20
Sep-03-19	Initiated	Piper Jaffray	Overweight	$40
Feb-27-19	Reiterated	Chardan Capital Markets	Buy	$30 → $40
Jul-03-18	Initiated	BofA/Merrill	Buy
Jul-03-18	Initiated	Barclays	Overweight

Feb-03-26 08:00AM	ZipBio and MeiraGTx Enter into Exclusive License Agreement to Advance First-in-Class AAV Gene Therapy for Geographic Atrophy (PR Newswire)
Nov-20-25 03:00PM	Graviton Bioscience to Present Selective ROCK2 Obesity Data at 8th Annual Evercore HealthCONx Conference (PR Newswire)
Nov-13-25 09:15AM	MeiraGTx Holdings PLC (MGTX) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
08:00AM	MeiraGTx Reports Third Quarter 2025 Financial and Operational Results (GlobeNewswire)
Nov-10-25 09:15AM	Voyager Therapeutics (VYGR) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Loading…
07:00AM	MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology (GlobeNewswire)
Nov-06-25 06:25PM	Alector (ALEC) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
Nov-05-25 05:35PM	Gossamer Bio (GOSS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
10:00AM	MeiraGTx Holdings PLC (MGTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-22-25 08:18AM	MeiraGTx (MGTX) Moves 12.4% Higher: Will This Strength Last? (Zacks) -5.62%
Oct-07-25 08:00AM	MeiraGTx Announces Two Posters at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress (GlobeNewswire)
Aug-14-25 09:10AM	MeiraGTx Holdings PLC (MGTX) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
08:35AM	Xilio Therapeutics, Inc. (XLO) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
08:00AM	MeiraGTx Reports Second Quarter 2025 Financial and Operational Results (GlobeNewswire)
Aug-07-25 08:45AM	InflaRx N.V. (IFRX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
08:03AM	Loading…
Jun-27-25 08:03AM	3 Promising Genomics Stocks to Keep an Eye On in 2025 (Zacks)
May-13-25 04:30PM	MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting (GlobeNewswire) -8.36% -10.00%
09:15AM	MeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
08:00AM	MeiraGTx Reports First Quarter 2025 Financial and Operational Results (GlobeNewswire)
May-09-25 08:00AM	MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson's Disease (GlobeNewswire)
Apr-10-25 09:49AM	Beam Therapeutics (BEAM) Moves 12.6% Higher: Will This Strength Last? (Zacks) -5.59%
Apr-01-25 11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks) -9.14%
Mar-25-25 10:50AM	MeiraGTx Holdings: Gaining Regulatory Focus (SeekingAlpha)
09:21AM	AnaptysBio (ANAB) Moves 9.5% Higher: Will This Strength Last? (Zacks)
Mar-18-25 03:29AM	MeiraGTx Holdings (MGTX) Partners with Hologen for $200M AI-Powered Parkinsons Treatment (Insider Monkey)
Mar-14-25 08:27AM	MeiraGTx and Hologen launch AI-backed gene therapy venture (Pharmaceutical Technology) -5.58%
Mar-13-25 08:05AM	MeiraGTx spins Parkinsons, obesity gene therapies into AI startup (BioPharma Dive) +28.71%
08:00AM	MeiraGTx Reports Fourth Quarter and Full Year 2024 Financial and Operational Results and Recent Business Updates (GlobeNewswire)
07:30AM	MeiraGTx Enters into a Strategic Collaboration with Hologen AI to Expedite Phase 3 Development of AAV-GAD for Parkinson's Disease and Industrialize MeiraGTx's Proprietary Manufacturing Process (GlobeNewswire)
Feb-24-25 07:30AM	MeiraGTx seeks UK approval after gene therapy restores sight in children born blind (Pharmaceutical Technology)
06:30AM	Loading…
Feb-21-25 06:30AM	MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy (GlobeNewswire) +6.88%
Jan-22-25 08:30AM	MeiraGTx Receives Rare Pediatric Disease Designation from FDA for AAV8-RK-RetGC for the Treatment of Patients with Leber Congenital Amaurosis due to GUCY2D Mutations (GlobeNewswire) -5.77%
Jan-20-25 03:25PM	Is MeiraGTx Holdings plc (MGTX) Among Billionaire Joseph Edelman's Long-Term Stock Picks? (Insider Monkey)
Dec-29-24 06:19AM	MeiraGTx Holdings plc (MGTX): Is This Gene Therapy Stock a Good Buy Right Now? (Insider Monkey)
Dec-10-24 09:38AM	MeiraGTx granted RMAT designation by U.S. FDA to AAV2-hAQP1 (TipRanks)
Dec-09-24 08:00AM	MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia (GlobeNewswire) +5.54%
Nov-24-24 07:27PM	Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors (PR Newswire)
Nov-13-24 09:15AM	MeiraGTx Holdings PLC (MGTX) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +5.71%
08:00AM	MeiraGTx Announces Third Quarter 2024 Financial and Operational Results and Recent Business Updates (GlobeNewswire)
Oct-22-24 08:00AM	MeiraGTx Announces Five Posters at the European Society of Gene and Cell Therapy (ESGCT) 2024 Annual Congress (GlobeNewswire)
Oct-16-24 04:43PM	MeiraGTxs Parkinsons gene therapy shows promise in Phase I/II study (Clinical Trials Arena) +11.07%
07:30AM	MeiraGTx Holdings Reports Promising Parkinsons Therapy Results (TipRanks)
06:45AM	MeiraGTx (MGTX) Surges 14.9%: Is This an Indication of Further Gains? (Zacks)
Oct-15-24 12:13PM	Small Cap-MeiraGTx Reveals Encouraging Data From Parkinson's Study Showing Significant, Clinically Meaningful Changes in Key Efficacy Endpoints (Benzinga) +14.87%
07:00AM	MeiraGTx Announces Positive Data from Randomized, Sham-controlled Clinical Bridging Study of AAV-GAD for the Treatment of Parkinson's Disease (GlobeNewswire)
Oct-09-24 04:30PM	MeiraGTx Announces Poster Presentation on a Potential Treatment for MC4R Genetic Deficiency at the 2024 Society for Neuroscience Conference (GlobeNewswire)
Aug-30-24 09:46AM	Is MeiraGTx Holdings plc (MGTX) The Best Rated Penny Stock To Buy According to Analysts? (Insider Monkey)
Aug-12-24 07:40AM	MeiraGTx Holdings PLC (MGTX) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -8.47%
07:05AM	MeiraGTx Announces $50 Million Offering of Ordinary Shares led by Sanofi and Reports Second Quarter 2024 Financial and Operational Results (GlobeNewswire)
07:03AM	MeiraGTx Announces Pricing of Offering of Ordinary Shares Led by Sanofi (GlobeNewswire)
May-24-24 09:57AM	Ireland the jewel in the life sciences crown? (Medical Device Network)
May-22-24 09:32AM	Jim Cramer is Recommending These Stocks (Insider Monkey)
May-10-24 03:09PM	MeiraGTx Holdings PLC Reports First Quarter 2024 Financial Results (GuruFocus.com)
May-09-24 01:53PM	MGTX Stock Earnings: MeiraGTx Hldgs Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:00AM	MeiraGTx Reports First Quarter 2024 Financial and Operational Results (GlobeNewswire)
Apr-24-24 04:30PM	MeiraGTx to Participate in Upcoming Investor Conferences (GlobeNewswire)
Apr-18-24 04:30PM	MeiraGTx Announces Oral Presentation at the 2024 American Academy of Oral Medicine (AAOM) Annual Conference (GlobeNewswire)
Mar-14-24 10:31AM	MeiraGTx Holdings PLC Reports Notable Clinical Progress Amidst Financial Challenges in 2023 (GuruFocus.com) -7.09%
09:45AM	MeiraGTx Holdings PLC (MGTX) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
08:30AM	MeiraGTx Reports Fourth Quarter and Full Year 2023 Financial and Operational Results and Recent Business Updates (GlobeNewswire)
Feb-13-24 08:00AM	MeiraGTx Announces $50 Million Milestone from Janssen Pharmaceuticals (GlobeNewswire) -9.55%
Feb-01-24 07:30AM	Graviton Bioscience Announces Strategic Investment from Sanofi to Advance Development of the Next Generation of Selective ROCK2 Inhibitors (PR Newswire)
Jan-10-24 09:55AM	Wall Street Analysts Think MeiraGTx Holdings PLC (MGTX) Could Surge 217.92%: Read This Before Placing a Bet (Zacks)
08:49AM	MeiraGTx (MGTX): Strong Industry, Solid Earnings Estimate Revisions (Zacks)
Jan-02-24 12:17PM	MeiraGTx (MGTX) Stock Surges 35% in a Month: Here's Why (Zacks)
Dec-25-23 09:55AM	Wall Street Analysts Believe MeiraGTx Holdings PLC (MGTX) Could Rally 221.78%: Here's is How to Trade (Zacks)
Dec-21-23 07:07AM	J&J bets bigger on MeiraGTxs eye gene therapy (BioPharma Dive) +32.59%
07:00AM	MeiraGTx Announces Asset Purchase Agreement Involving its AAV-RPGR Collaboration for up to $415 million (GlobeNewswire)
Nov-21-23 04:30PM	MeiraGTx to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-14-23 07:21PM	MeiraGTx Holdings PLC Reports Q3 2023 Financial Results and Operational Progress (GuruFocus.com)
08:00AM	MeiraGTx Announces Third Quarter 2023 Financial and Operational Results (GlobeNewswire)
Oct-31-23 08:00AM	BestGrowthStocks.Com: MeiraGTx Holdings plc Actively Pursuing Strategic Partnerships and Asset Interest, Potential Transactions (News Direct)
Oct-30-23 08:25AM	Sanofi invests in MeiraGTx and its gene-regulating technology (BioPharma Dive) +20.27%
07:30AM	MeiraGTx Announces $30 Million Strategic Investment from Sanofi; Company Pursuing Multiple Additional Strategic Opportunities (GlobeNewswire)
Oct-24-23 08:30AM	MeiraGTx Announces an Oral Presentation and Eight Posters at the European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress (GlobeNewswire)
Aug-10-23 09:15AM	MeiraGTx Holdings PLC (MGTX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
08:00AM	MeiraGTx Reports Second Quarter 2023 Financial and Operational Results (GlobeNewswire)
Aug-01-23 09:10AM	MeiraGTx Announces Poster Presentation at the 2023 American Society of Gene and Cell Therapy (ASGCT) Spotlight on Immuno-Oncology (GlobeNewswire)
Jul-19-23 08:30AM	MeiraGTx Announces its Wholly-Owned Gene Therapy Manufacturing Facility in Shannon, Ireland has Received Commercial MIA Authorization for QC Testing (GlobeNewswire) +8.04%
Jun-28-23 07:53PM	MeiraGTx Holdings PLC (MGTX) Soars 8.2%: Is Further Upside Left in the Stock? (Zacks) +8.20%
Jun-27-23 03:41PM	MeiraGTx's Investigational Drug Shows Improved Symptoms In Radiation-Induced Oral Dryness (Benzinga) -7.31%
07:30AM	MeiraGTx Announces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia (GlobeNewswire)
Jun-22-23 04:01PM	MeiraGTx to Present 12-month Data from All Cohorts of the Completed Phase 1 AQUAx Clinical Study and an Update on the Companys Recently Initiated Phase 2 Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Tuesday, June 27, 2023 (GlobeNewswire)
Jun-16-23 10:00AM	MeiraGTx Holdings (NASDAQ:MGTX) shareholders have endured a 43% loss from investing in the stock three years ago (Simply Wall St.)
Jun-02-23 09:55AM	Does MeiraGTx Holdings PLC (MGTX) Have the Potential to Rally 320.9% as Wall Street Analysts Expect? (Zacks) +9.29%
May-17-23 09:55AM	Wall Street Analysts Predict a 314.29% Upside in MeiraGTx Holdings PLC (MGTX): Here's What You Should Know (Zacks) +10.00%
May-16-23 09:00AM	MeiraGTx Announces the Presentation of Nine Posters at the American Society of Gene and Cell Therapy (ASGCT) 2023 Annual Meeting (GlobeNewswire) +13.82%
May-11-23 08:00AM	MeiraGTx Reports First Quarter 2023 Financial and Operational Results (GlobeNewswire) -5.97%
May-03-23 08:30AM	MeiraGTx Announces $60 Million Private Placement of Ordinary Shares (GlobeNewswire) +12.52%
Apr-21-23 08:30AM	MeiraGTx Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting (GlobeNewswire)
Apr-20-23 05:00PM	MeiraGTx to Participate in Upcoming Investor Conferences (GlobeNewswire)
Apr-12-23 11:41AM	MeiraGTx Holdings plc (NASDAQ:MGTX) has caught the attention of institutional investors who hold a sizeable 31% stake (Simply Wall St.)
Mar-16-23 06:06AM	A Look At The Intrinsic Value Of MeiraGTx Holdings plc (NASDAQ:MGTX) (Simply Wall St.)
Mar-14-23 08:00AM	MeiraGTx Reports Fourth Quarter and Full Year 2022 Financial and Operational Results (GlobeNewswire)
Feb-13-23 03:00AM	JNJ Bought Up Biotech Stock MeiraGTx. It Sold Procept BioRobotics. (Barrons.com) +7.74%
Dec-13-22 01:56PM	MeiraGTx's Investigational Candidate Shows Improvement In Radiation Induced Dry Mouth Symptoms (Benzinga)
07:30AM	MeiraGTx Announces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia (GlobeNewswire)
06:26AM	MeiraGTx Holdings (NASDAQ:MGTX) investors are sitting on a loss of 71% if they invested three years ago (Simply Wall St.)
Dec-08-22 04:30PM	MeiraGTx to Present Clinical Data from Phase 1 Trial of AAV-hAQP1 for Radiation-Induced Xerostomia on Tuesday, December 13, 2022 (GlobeNewswire)
Nov-22-22 04:30PM	MeiraGTx to Participate in Upcoming Investor Conferences (GlobeNewswire)

MeiraGTx Holdings Plc is a clinical-stage genetic medicines company with a broad pipeline of late-stage clinical programs, including Parkinson's disease, radiation-induced xerostomia and AIPL1-associated retinal dystrophy. It targets local delivery of small doses of genetic medicines to treat both inherited and more common conditions with severe unmet needs. The company was founded on March 20, 2015 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Giroux Richard	CFO & COO	Oct 21 '25	Sale	8.87	24,000	212,880	829,494	Oct 21 09:19 PM
Richard Giroux	Officer	Oct 21 '25	Proposed Sale	8.87	24,000	212,880		Oct 21 09:17 PM
Forbes Alexandria	PRESIDENT & CEO	Oct 07 '25	Sale	8.39	47,500	398,525	1,313,983	Oct 07 09:49 PM
Alexandria Forbes	Officer	Oct 07 '25	Proposed Sale	8.39	47,500	398,525		Oct 07 09:47 PM
Giroux Richard	CFO & COO	Jul 22 '25	Sale	8.52	24,000	204,480	853,494	Jul 22 09:01 PM
Richard Giroux	Officer	Jul 22 '25	Proposed Sale	8.52	24,000	204,480		Jul 22 08:58 PM
Forbes Alexandria	PRESIDENT & CEO	Jul 08 '25	Sale	7.97	47,500	378,575	1,361,483	Jul 08 08:57 PM
Alexandria Forbes	Officer	Jul 08 '25	Proposed Sale	7.97	47,500	378,575		Jul 08 08:55 PM
Giroux Richard	CFO & COO	Apr 22 '25	Sale	6.00	24,000	144,000	882,494	Apr 22 08:54 PM
Richard Giroux	Officer	Apr 22 '25	Proposed Sale	6.00	24,000	144,000		Apr 22 08:52 PM
Forbes Alexandria	PRESIDENT & CEO	Apr 08 '25	Sale	5.34	47,500	253,650	1,408,983	Apr 08 09:05 PM
Forbes Alexandria	President / CEO	Apr 08 '25	Proposed Sale	5.29	47,500	251,265		Apr 08 04:55 PM

LYRA

Lyra Therapeutics Inc

OBIO

Orchestra BioMed Holdings Inc

ACRV

Acrivon Therapeutics Inc

ALDX

Aldeyra Therapeutics Inc

SLDB

Solid Biosciences Inc

MGTX

MeiraGTx Holdings plc

Upgrade your FINVIZ experience